CD80	B-protein
and	O
CD86	B-protein
are	O
not	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
CD28	B-protein
.	O

Ligation	O
of	O
either	O
CD80	B-protein
(	O
B7-1	B-protein
)	O
or	O
CD86	B-protein
(	O
B7-2	B-protein
)	O
,	O
two	O
principal	O
ligands	O
for	O
CD28	B-protein
,	O
is	O
thought	O
to	O
skew	O
the	O
immune	O
response	O
toward	O
Th1	O
or	O
Th2	O
differentiation	O
.	O

We	O
have	O
examined	O
early	O
signal	O
transduction	O
pathways	O
recruited	O
following	O
T	O
cell	O
stimulation	O
with	O
either	O
CD80	B-protein
or	O
CD86	B-protein
.	O

Purified	B-cell_line
human	I-cell_line
peripheral	I-cell_line
T	I-cell_line
cells	I-cell_line
or	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
stimulated	O
with	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
expressing	O
either	O
human	B-protein
CD80	I-protein
(	O
CHO-CD80	B-protein
)	O
or	O
human	B-protein
CD86	I-protein
(	O
CHO-CD86	B-protein
)	O
or	O
with	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
.	O

In	O
the	O
presence	O
of	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
both	O
CHO-CD80	B-protein
and	O
CHO-CD86	B-protein
,	O
like	O
anti-CD28	B-protein
mAb	I-protein
,	O
were	O
capable	O
of	O
stimulating	O
cytokine	B-protein
production	O
from	O
both	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Both	O
CHO-CD80	B-protein
and	O
CHO-CD86	B-protein
,	O
in	O
the	O
presence	O
of	O
anti-CD3	B-protein
mAb	I-protein
,	O
costimulated	O
NFAT	B-protein
-dependent	O
transcriptional	O
activation	O
.	O

Several	O
intracellular	O
signaling	B-protein
proteins	I-protein
,	O
such	O
as	O
CBL	B-protein
and	O
VAV	B-protein
,	O
were	O
phosphorylated	O
on	O
tyrosine	O
in	O
response	O
to	O
CD80	B-protein
,	O
CD86	B-protein
,	O
and	O
anti-CD28	B-protein
mAb	I-protein
.	O

Surprisingly	O
,	O
although	O
stimulation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
either	O
CHO-CD80	B-protein
or	O
anti-CD28	B-protein
mAb	I-protein
resulted	O
in	O
robust	O
tyrosine	O
phosphorylation	O
of	O
CD28	B-protein
itself	O
,	O
ligation	O
with	O
CHO-CD86	B-protein
was	O
unable	O
to	O
induce	O
detectable	O
CD28	B-protein
tyrosyl	O
phosphorylation	O
over	O
a	O
range	O
of	O
stimulation	O
conditions	O
.	O

In	O
addition	O
,	O
the	O
association	O
of	O
phosphoinositide	B-protein
3-kinase	I-protein
with	O
CD28	B-protein
and	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	O
Cgamma	O
were	O
seen	O
after	O
anti-CD28	O
mAb	O
and	O
CHO-CD80	O
stimulation	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
after	O
CHO-CD86	B-protein
stimulation	O
.	O

Thus	O
,	O
ligation	O
of	O
CD28	B-protein
with	O
either	O
CD80	B-protein
or	O
CD86	B-protein
leads	O
to	O
shared	O
early	O
signal	O
transduction	O
events	O
such	O
as	O
the	O
tyrosine	O
phosphorylation	O
of	O
CBL	B-protein
and	O
VAV	B-protein
,	O
to	O
NFAT	B-protein
-mediated	O
transcriptional	O
activation	O
,	O
and	O
to	O
the	O
costimulation	O
of	O
interleukin-2	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
production	O
.	O

However	O
,	O
CD80	B-protein
and	O
CD86	B-protein
also	O
induce	O
distinct	O
signal	O
transduction	O
pathways	O
including	O
the	O
tyrosine	O
phosphorylation	O
of	O
CD28	B-protein
and	O
phospholipase	B-protein
Cgamma1	I-protein
and	O
the	O
SH2	B-protein
-dependent	O
association	O
of	O
phosphoinositide	B-protein
3-kinase	I-protein
with	O
CD28	B-protein
.	O

These	O
quantitative	O
,	O
if	O
not	O
qualitative	O
,	O
differences	O
between	O
signaling	O
initiated	O
by	O
these	O
two	O
ligands	O
for	O
CD28	B-protein
may	O
contribute	O
to	O
functional	O
differences	O
(	O
e.g.	O
Th1	O
or	O
Th2	O
differentiation	O
)	O
in	O
T	O
cell	O
responses	O
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

274	NULL
,	NULL
No	NULL
.	NULL

5	NULL
,	NULL
Issue	NULL
of	NULL
January	NULL
29	NULL
,	NULL
pp	NULL
.	NULL

3116-3124	NULL
,	NULL
1999	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
CD80	NULL
and	NULL
CD86	NULL
Are	NULL
Not	NULL
Equivalent	NULL
in	NULL
Their	NULL
Ability	NULL
to	NULL
Induce	NULL
the	NULL
Tyrosine	NULL
Phosphorylation	NULL
of	NULL
CD28*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
July	NULL
7	NULL
,	NULL
1998	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
October	NULL
27	NULL
,	NULL
1998	NULL
)	NULL
Jacqueline	NULL
M.	NULL
Slavik	NULL
}	NULL
,	NULL
Jill	NULL
E.	NULL
Hutchcroft	NULL
$	NULL
§	NULL
,	NULL
and	NULL
Barbara	NULL
E.	NULL
Bierer	NULL
#	NULL
]	NULL
]	NULL
From	NULL
the	NULL
{	NULL
Department	NULL
of	NULL
Pediatric	NULL
Oncology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
the	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
,	NULL
and	NULL
the	NULL
§Department	NULL
of	NULL
Biochemistry	NULL
,	NULL
Purdue	NULL
University	NULL
,	NULL
West	NULL
Lafayette	NULL
,	NULL
Indiana	NULL
47907	NULL
Ligation	NULL
of	NULL
either	NULL
CD80	NULL
(	NULL
B7-1	NULL
)	NULL
or	NULL
CD86	NULL
(	NULL
B7-2	NULL
)	NULL
,	NULL
two	NULL
principal	NULL
ligands	NULL
for	NULL
CD28	NULL
,	NULL
is	NULL
thought	NULL
to	NULL
skew	NULL
the	NULL
immune	NULL
response	NULL
toward	NULL
Thl	NULL
or	NULL
Th2	NULL
differentiation	NULL
.	NULL

We	NULL
have	NULL
examined	NULL
early	NULL
signal	NULL
transduction	NULL
pathways	NULL
recruited	NULL
following	NULL
T	NULL
cell	NULL
stimulation	NULL
with	NULL
either	NULL
CD80	NULL
or	NULL
CD86	NULL
.	NULL

Purified	NULL
human	NULL
peripheral	NULL
T	NULL
cells	NULL
or	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
(	NULL
CHO	NULL
)	NULL
cells	NULL
expressing	NULL
either	NULL
human	NULL
CD80	NULL
(	NULL
CHO-CD80	NULL
)	NULL
or	NULL
human	NULL
CD86	NULL
(	NULL
CHO-CD86	NULL
)	NULL
or	NULL
with	NULL
anti-CD28	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
,	NULL
both	NULL
CHO-CD80	NULL
and	NULL
CHO-CD86	NULL
,	NULL
like	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
were	NULL
capable	NULL
of	NULL
stimulating	NULL
cytokine	NULL
production	NULL
from	NULL
both	NULL
human	NULL
peripheral	NULL
T	NULL
cells	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Both	NULL
CHO-CD80	NULL
and	NULL
CHO-CD86	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CD3	NULL
mAb	NULL
,	NULL
costimulated	NULL
NFAT-dependent	NULL
transcriptional	NULL
activation	NULL
.	NULL

Several	NULL
intracellular	NULL
signaling	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
CBL	NULL
and	NULL
VAV	NULL
,	NULL
were	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
in	NULL
response	NULL
to	NULL
CD80	NULL
,	NULL
CD86	NULL
,	NULL
and	NULL
anti-CD28	NULL
mAb	NULL
.	NULL

Surprisingly	NULL
,	NULL
although	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
either	NULL
CHO-CD80	NULL
or	NULL
anti-CD28	NULL
mAb	NULL
resulted	NULL
in	NULL
robust	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
itself	NULL
,	NULL
ligation	NULL
with	NULL
CHO-CD86	NULL
was	NULL
unable	NULL
to	NULL
induce	NULL
detectable	NULL
CD28	NULL
tyrosyl	NULL
phosphorylation	NULL
over	NULL
a	NULL
range	NULL
of	NULL
stimulation	NULL
conditions	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
association	NULL
of	NULL
phosphoinositide	NULL
3-kinase	NULL
with	NULL
CD28	NULL
and	NULL
enhanced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
phospholipase	NULL
Cy	NULL
were	NULL
seen	NULL
after	NULL
anti-CD28	NULL
mAb	NULL
and	NULL
CHO-CD80	NULL
stimulation	NULL
but	NULL
to	NULL
a	NULL
much	NULL
lesser	NULL
extent	NULL
after	NULL
CHO-CD86	NULL
stimulation	NULL
.	NULL

Thus	NULL
,	NULL
ligation	NULL
of	NULL
CD28	NULL
with	NULL
either	NULL
CD80	NULL
or	NULL
CD86	NULL
leads	NULL
to	NULL
shared	NULL
early	NULL
signal	NULL
transduction	NULL
events	NULL
such	NULL
as	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CBL	NULL
and	NULL
VAV	NULL
,	NULL
to	NULL
NFAT	NULL
-medi-ated	NULL
transcriptional	NULL
activation	NULL
,	NULL
and	NULL
to	NULL
the	NULL
costimulation	NULL
of	NULL
interleukin-2	NULL
and	NULL
granulocyte-	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
production	NULL
.	NULL

However	NULL
,	NULL
CD80	NULL
and	NULL
CD86	NULL
also	NULL
induce	NULL
distinct	NULL
signal	NULL
transduction	NULL
pathways	NULL
including	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
and	NULL
phospholipase	NULL
Cyl	NULL
and	NULL
the	NULL
SH2-dependent	NULL
association	NULL
of	NULL
phosphoinositide	NULL
3-kinase	NULL
with	NULL
CD28	NULL
.	NULL

These	NULL
quantita-tive	NULL
,	NULL
if	NULL
not	NULL
qualitative	NULL
,	NULL
differences	NULL
between	NULL
signaling	NULL
initiated	NULL
by	NULL
these	NULL
two	NULL
ligands	NULL
for	NULL
CD28	NULL
may	NULL
contribute	NULL
to	NULL
functional	NULL
differences	NULL
(	NULL
e.g	NULL
.	NULL

Thl	NULL
or	NULL
Th2	NULL
differentia-tion	NULL
)	NULL
in	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

Activation	NULL
and	NULL
maturation	NULL
of	NULL
resting	NULL
T	NULL
lymphocytes	NULL
can	NULL
be	NULL
achieved	NULL
by	NULL
antigen-specific	NULL
interactions	NULL
of	NULL
the	NULL
TeR-CD3	NULL
com	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

|	NULL
To	NULL
whom	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
NHLBI	NULL
,	NULL
Bldg	NULL
.	NULL

10	NULL
,	NULL
Rm	NULL
.	NULL

5D49	NULL
,	NULL
10	NULL
Center	NULL
Dr.	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
301-402-6786	NULL
;	NULL
Fax	NULL
:	NULL
301-480-1792	NULL
;	NULL
E-mail	NULL
:	NULL
BiererB	NULL
@	NULL
nih.gov	NULL
.	NULL

3116	NULL
plex	NULL
in	NULL
concert	NULL
with	NULL
a	NULL
second	NULL
,	NULL
antigen-nonspecific	NULL
signal	NULL
.	NULL

This	NULL
second	NULL
,	NULL
costimulatory	NULL
signal	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
prevent	NULL
the	NULL
induction	NULL
of	NULL
T	NULL
cell	NULL
anergy	NULL
and	NULL
to	NULL
enhance	NULL
cytokine	NULL
production	NULL
,	NULL
notably	NULL
IL-2	NULL
``	NULL
(	NULL
1-8	NULL
)	NULL
.	NULL

Found	NULL
on	NULL
more	NULL
than	NULL
95	NULL
%	NULL
of	NULL
human	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
on	NULL
about	NULL
50	NULL
%	NULL
of	NULL
human	NULL
CD8*	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
cell-surface	NULL
molecule	NULL
CD28	NULL
is	NULL
a	NULL
major	NULL
T	NULL
cell	NULL
costimulatory	NULL
receptor	NULL
.	NULL

Engagement	NULL
of	NULL
the	NULL
CD28	NULL
receptor	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
or	NULL
by	NULL
ligand	NULL
prevents	NULL
the	NULL
induction	NULL
of	NULL
T	NULL
cell	NULL
anergy	NULL
and	NULL
supports	NULL
IL-2	NULL
production	NULL
and	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

The	NULL
B7	NULL
family	NULL
members	NULL
CD80	NULL
(	NULL
B7-1	NULL
)	NULL
and	NULL
CD86	NULL
(	NULL
B7-2	NULL
)	NULL
are	NULL
two	NULL
principal	NULL
ligands	NULL
for	NULL
CD28	NULL
and	NULL
for	NULL
CTLA-4	NULL
(	NULL
CD152	NULL
)	NULL
,	NULL
a	NULL
second	NULL
CD28	NULL
family	NULL
member	NULL
.	NULL

Whereas	NULL
only	NULL
25	NULL
%	NULL
homologous	NULL
by	NULL
amino	NULL
acid	NULL
sequence	NULL
,	NULL
CD80	NULL
and	NULL
CD86	NULL
bind	NULL
CD28	NULL
with	NULL
similar	NULL
low	NULL
affinities	NULL
and	NULL
bind	NULL
CTLA-4	NULL
with	NULL
similar	NULL
high	NULL
affinities	NULL
(	NULL
4	NULL
)	NULL
.	NULL

However	NULL
,	NULL
CD86	NULL
has	NULL
faster	NULL
dissociation	NULL
kinetics	NULL
than	NULL
CD80	NULL
(	NULL
5	NULL
)	NULL
,	NULL
and	NULL
independent	NULL
mutational	NULL
analyses	NULL
have	NULL
confirmed	NULL
that	NULL
CD80	NULL
and	NULL
CD86	NULL
bind	NULL
to	NULL
overlapping	NULL
but	NULL
not	NULL
identical	NULL
sites	NULL
on	NULL
CD28	NULL
(	NULL
6-9	NULL
)	NULL
.	NULL

The	NULL
cell-surface	NULL
expression	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
differs	NULL
both	NULL
quantitatively	NULL
and	NULL
qualitatively	NULL
on	NULL
antigen	NULL
presenting	NULL
cells	NULL
.	NULL

CD86	NULL
is	NULL
expressed	NULL
constitutively	NULL
on	NULL
resting	NULL
monocytes	NULL
and	NULL
can	NULL
be	NULL
rapidly	NULL
induced	NULL
on	NULL
activated	NULL
B	NULL
cells	NULL
(	NULL
10	NULL
)	NULL
.	NULL

CD80	NULL
is	NULL
not	NULL
expressed	NULL
on	NULL
resting	NULL
monocytes	NULL
and	NULL
only	NULL
minimally	NULL
on	NULL
dendritic	NULL
cells	NULL
and	NULL
,	NULL
although	NULL
expression	NULL
can	NULL
be	NULL
induced	NULL
on	NULL
activated	NULL
macrophages	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
NK	NULL
cells	NULL
,	NULL
the	NULL
time	NULL
course	NULL
of	NULL
CD80	NULL
induction	NULL
of	NULL
expression	NULL
is	NULL
slower	NULL
than	NULL
of	NULL
that	NULL
of	NULL
CD86	NULL
(	NULL
11	NULL
)	NULL
,	NULL
A	NULL
growing	NULL
body	NULL
of	NULL
evidence	NULL
suggests	NULL
that	NULL
there	NULL
are	NULL
different	NULL
functional	NULL
consequences	NULL
of	NULL
CD28	NULL
engagement	NULL
by	NULL
CD80	NULL
and	NULL
CD86	NULL
(	NULL
12-17	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
blocking	NULL
the	NULL
interaction	NULL
between	NULL
CD28	NULL
and	NULL
CD80	NULL
with	NULL
anti-CD80	NULL
mAb	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
increase	NULL
IL-4	NULL
production	NULL
in	NULL
mice	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Conversely	NULL
,	NULL
blocking	NULL
the	NULL
interaction	NULL
of	NULL
CD86	NULL
with	NULL
CD28	NULL
in	NULL
vitro	NULL
was	NULL
shown	NULL
to	NULL
increase	NULL
the	NULL
production	NULL
of	NULL
interferon-y	NULL
(	NULL
13	NULL
)	NULL
.	NULL

These	NULL
data	NULL
from	NULL
murine	NULL
systems	NULL
support	NULL
a	NULL
model	NULL
whereby	NULL
CD80	NULL
costimulation	NULL
promotes	NULL
the	NULL
development	NULL
of	NULL
Th1	NULL
cells	NULL
,	NULL
whereas	NULL
CD86	NULL
costimulation	NULL
drives	NULL
differentiation	NULL
toward	NULL
Th2	NULL
cells	NULL
.	NULL

Costimulation	NULL
of	NULL
resting	NULL
CD4	NULL
``	NULL
human	NULL
T	NULL
cells	NULL
with	NULL
CD80	NULL
or	NULL
CD86	NULL
resulted	NULL
in	NULL
equivalent	NULL
IL-2	NULL
and	NULL
interferon-y	NULL
production	NULL
(	NULL
18	NULL
)	NULL
.	NULL

However	NULL
,	NULL
costimulation	NULL
with	NULL
CD80	NULL
resulted	NULL
in	NULL
more	NULL
GM-CSF	NULL
production	NULL
than	NULL
with	NULL
CD86	NULL
,	NULL
whereas	NULL
costimulation	NULL
with	NULL
CD86	NULL
gave	NULL
more	NULL
efficient	NULL
production	NULL
of	NULL
IL-4	NULL
and	NULL
TNF-	NULL
than	NULL
with	NULL
CD80	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
CD86	NULL
costimulation	NULL
appeared	NULL
to	NULL
direct	NULL
the	NULL
immune	NULL
response	NULL
toward	NULL
Th2	NULL
development	NULL
,	NULL
whereas	NULL
CD80	NULL
provided	NULL
a	NULL
less	NULL
directive	NULL
(	NULL
and	NULL
therefore	NULL
Thl-like	NULL
)	NULL
signal	NULL
.	NULL

These	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
human	NULL
CD80	NULL
but	NULL
not	NULL
CD86	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
CHO	NULL
,	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
;	NULL
PLC	NULL
,	NULL
phospholipase	NULL
C	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
GM-CSF	NULL
,	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
;	NULL
FCS	NULL
,	NULL
fetal	NULL
calf	NULL
serum	NULL
;	NULL
PIS-K	NULL
,	NULL
phosphoinositide	NULL
3-ki-nase	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
;	NULL
PAGE	NULL
,	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
;	NULL
PVDF	NULL
,	NULL
polyvinylidene	NULL
difluoride	NULL
;	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Differential	NULL
Signaling	NULL
through	NULL
CD28	NULL
by	NULL
Ligands	NULL
CD80	NULL
and	NULL
CD86	NULL
3117	NULL
was	NULL
able	NULL
to	NULL
generate	NULL
human	NULL
cytolytic	NULL
effector	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
CD86	NULL
is	NULL
less	NULL
effective	NULL
than	NULL
CD80	NULL
at	NULL
down-regulating	NULL
CD28	NULL
expression	NULL
after	NULL
ligation	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
provide	NULL
evidence	NULL
that	NULL
the	NULL
functional	NULL
outcome	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
costimulation	NULL
may	NULL
differ	NULL
.	NULL

A	NULL
limited	NULL
number	NULL
of	NULL
studies	NULL
have	NULL
directly	NULL
compared	NULL
the	NULL
signals	NULL
generated	NULL
following	NULL
CD80	NULL
or	NULL
CD86	NULL
engagement	NULL
of	NULL
CD28	NULL
(	NULL
19-22	NULL
)	NULL
,	NULL
but	NULL
no	NULL
differences	NULL
have	NULL
been	NULL
observed	NULL
that	NULL
correlate	NULL
with	NULL
the	NULL
differences	NULL
in	NULL
structure	NULL
and	NULL
function	NULL
between	NULL
CD80	NULL
and	NULL
CD86	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
compared	NULL
the	NULL
intracellular	NULL
signals	NULL
generated	NULL
by	NULL
engagement	NULL
of	NULL
human	NULL
CD28	NULL
with	NULL
either	NULL
anti-CD28	NULL
mAb	NULL
or	NULL
with	NULL
CHO	NULL
cells	NULL
transfected	NULL
with	NULL
human	NULL
CD80	NULL
or	NULL
human	NULL
CD86	NULL
.	NULL

We	NULL
have	NULL
used	NULL
both	NULL
purified	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
and	NULL
CD4*	NULL
T	NULL
cells	NULL
isolated	NULL
by	NULL
negative	NULL
selection	NULL
.	NULL

Additionally	NULL
,	NULL
we	NULL
have	NULL
used	NULL
a	NULL
Jurkat	NULL
T	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
expressed	NULL
CD28	NULL
but	NULL
did	NULL
not	NULL
express	NULL
CTLA-4	NULL
,	NULL
to	NULL
eliminate	NULL
any	NULL
contribution	NULL
of	NULL
CTLA-4	NULL
ligation	NULL
by	NULL
ligand	NULL
to	NULL
signaling	NULL
differences	NULL
observed	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
that	NULL
CHO	NULL
cells	NULL
transfected	NULL
with	NULL
either	NULL
human	NULL
CD80	NULL
(	NULL
CHO-CD80	NULL
)	NULL
or	NULL
human	NULL
CD86	NULL
(	NULL
CHO-CD86	NULL
)	NULL
were	NULL
capable	NULL
of	NULL
costimulating	NULL
IL-2	NULL
production	NULL
both	NULL
from	NULL
purified	NULL
human	NULL
peripheral	NULL
T	NULL
cells	NULL
and	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
second	NULL
signal	NULL
provided	NULL
by	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
costimulating	NULL
GM-CSF	NULL
production	NULL
from	NULL
purified	NULL
human	NULL
peripheral	NULL
T	NULL
cells	NULL
.	NULL

Both	NULL
CHO-CD80	NULL
and	NULL
CHO-CD86	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CD3	NULL
,	NULL
costimulated	NULL
NFAT-mediated	NULL
transcriptional	NULL
activation	NULL
.	NULL

Similar	NULL
but	NULL
not	NULL
identical	NULL
patterns	NULL
of	NULL
phosphoproteins	NULL
were	NULL
revealed	NULL
following	NULL
stimulation	NULL
of	NULL
either	NULL
Jurkat	NULL
T	NULL
cells	NULL
or	NULL
human	NULL
purified	NULL
T	NULL
cells	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
CHO-CD80	NULL
,	NULL
or	NULL
CHO-CD86	NULL
.	NULL

We	NULL
identified	NULL
two	NULL
of	NULL
the	NULL
higher	NULL
molecular	NULL
weight	NULL
phosphoproteins	NULL
as	NULL
CBL	NULL
and	NULL
VAV	NULL
.	NULL

In	NULL
striking	NULL
contrast	NULL
,	NULL
however	NULL
,	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
CHO-CD80	NULL
,	NULL
but	NULL
not	NULL
with	NULL
CHO-CD86	NULL
,	NULL
resulted	NULL
in	NULL
robust	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
itself	NULL
.	NULL

Furthermore	NULL
,	NULL
considerably	NULL
less	NULL
PI3-K	NULL
was	NULL
associated	NULL
with	NULL
CD28	NULL
after	NULL
CD86	NULL
stimulation	NULL
compared	NULL
with	NULL
CD80	NULL
or	NULL
anti-CD28	NULL
mAb	NULL
stimulation	NULL
.	NULL

Correlating	NULL
with	NULL
the	NULL
difference	NULL
in	NULL
CD28	NULL
phosphorylation	NULL
and	NULL
PI3-K	NULL
association	NULL
was	NULL
the	NULL
induction	NULL
of	NULL
PLC-y1	NULL
phosphorylation	NULL
after	NULL
stimulation	NULL
with	NULL
CHO-CD80	NULL
but	NULL
not	NULL
with	NULL
CHO-CD86	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
signal	NULL
transmission	NULL
pathways	NULL
recruited	NULL
by	NULL
CD80	NULL
and	NULL
CD86	NULL
ligation	NULL
of	NULL
CD28	NULL
appear	NULL
to	NULL
differ	NULL
quantitatively	NULL
,	NULL
if	NULL
not	NULL
qualitatively	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Cells	NULL
and	NULL
Cell	NULL
Culture-The	NULL
human	NULL
T	NULL
leukemia	NULL
cell	NULL
line	NULL
Jurkat	NULL
(	NULL
clone	NULL
J77	NULL
)	NULL
was	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
Kendall	NULL
Smith	NULL
(	NULL
Cornell	NULL
University	NULL
,	NULL
New	NULL
York	NULL
)	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocytes	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
whole	NULL
blood	NULL
of	NULL
normal	NULL
donors	NULL
by	NULL
centrifugation	NULL
through	NULL
Ficoll-Hypaque	NULL
(	NULL
SG	NULL
1.007	NULL
,	NULL
Organon	NULL
Teknika	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
,	NULL
plastic	NULL
adher-ence	NULL
,	NULL
and	NULL
nylon	NULL
wool	NULL
filtration	NULL
.	NULL

Contaminating	NULL
erythrocytes	NULL
were	NULL
lysed	NULL
with	NULL
Tris-buffered	NULL
ammonium	NULL
chloride	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
CD8	NULL
T	NULL
cells	NULL
were	NULL
depleted	NULL
following	NULL
serial	NULL
incubation	NULL
with	NULL
5	NULL
ug/ml	NULL
OKT8	NULL
and	NULL
anti-mouse	NULL
Ig	NULL
microbeads	NULL
using	NULL
the	NULL
MACs	NULL
magnetic	NULL
cell	NULL
separation	NULL
system	NULL
(	NULL
Miltenyi	NULL
Biotech	NULL
,	NULL
Inc.	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Purified	NULL
T	NULL
cells	NULL
or	NULL
purified	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
rested	NULL
overnight	NULL
at	NULL
37°C	NULL
prior	NULL
to	NULL
use	NULL
.	NULL

Lymphocytes	NULL
were	NULL
cultured	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Me-diatech	NULL
,	NULL
Herndon	NULL
,	NULL
VA	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
,	NULL
Sigma	NULL
)	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.2	NULL
(	NULL
M.A	NULL
.	NULL

Bioproducts	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
and	NULL
50	NULL
uM	NULL
2-mercaptoethanol	NULL
(	NULL
Sigma	NULL
)	NULL
(	NULL
termed	NULL
10	NULL
%	NULL
RPMI	NULL
)	NULL
.	NULL

Chinese	NULL
hamster	NULL
ovary	NULL
(	NULL
CHO	NULL
)	NULL
cells	NULL
transfected	NULL
with	NULL
human	NULL
CD80	NULL
or	NULL
human	NULL
CD86	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
G.	NULL
Freeman	NULL
(	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle's/F12	NULL
medium	NULL
(	NULL
Cellgro	NULL
,	NULL
Fisher	NULL
)	NULL
containing	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
,	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.2	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
15	NULL
pg/ml	NULL
gentamicin	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
plus	NULL
400	NULL
pg/ml	NULL
geneticin	NULL
(	NULL
G418	NULL
)	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

CHO	NULL
cells	NULL
were	NULL
detached	NULL
from	NULL
10-mm	NULL
``	NULL
Petri	NULL
dishes	NULL
with	NULL
1:5000	NULL
Versene	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
for	NULL
5	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
and	NULL
washed	NULL
before	NULL
use	NULL
.	NULL

CHO	NULL
transfectants	NULL
were	NULL
monitored	NULL
periodically	NULL
to	NULL
verify	NULL
comparable	NULL
and	NULL
invariant	NULL
cell-surface	NULL
expression	NULL
of	NULL
B7	NULL
family	NULL
proteins	NULL
.	NULL

All	NULL
cell	NULL
lines	NULL
were	NULL
mycoplasma	NULL
negative	NULL
,	NULL
as	NULL
verified	NULL
by	NULL
routine	NULL
screening	NULL
with	NULL
the	NULL
mycoplasma	NULL
set	NULL
primer	NULL
(	NULL
Stratagene	NULL
,	NULL
Lia	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Antibodies-The	NULL
anti-human	NULL
CD28	NULL
mAb	NULL
9.3	NULL
(	NULL
Squibb	NULL
)	NULL
,	NULL
the	NULL
murine	NULL
anti-human	NULL
CD3	NULL
mAb	NULL
OKT3	NULL
,	NULL
and	NULL
the	NULL
anti-human	NULL
mAb	NULL
OKTS8D	NULL
(	NULL
Amer-ican	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
were	NULL
used	NULL
as	NULL
purified	NULL
ascites	NULL
fluid	NULL
.	NULL

The	NULL
horseradish	NULL
peroxidase	NULL
coupled	NULL
anti-phosphotyrosine	NULL
mAb	NULL
RC20	NULL
was	NULL
purchased	NULL
from	NULL
Transduction	NULL
Laboratories	NULL
(	NULL
Lexington	NULL
,	NULL
KY	NULL
)	NULL
.	NULL

The	NULL
agarose-conjugated	NULL
anti-phosphotyrosine	NULL
mAb	NULL
,	NULL
the	NULL
polyclonal	NULL
anti-VAV	NULL
,	NULL
the	NULL
polyclonal	NULL
anti-CBL	NULL
,	NULL
and	NULL
the	NULL
polyclonal	NULL
anti-PLCy1	NULL
were	NULL
all	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
Polyclonal	NULL
antisera	NULL
against	NULL
the	NULL
p85	NULL
subunit	NULL
of	NULL
PIS-K	NULL
was	NULL
purchased	NULL
from	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

The	NULL
anti-human	NULL
CD80	NULL
mAb	NULL
183	NULL
was	NULL
the	NULL
gift	NULL
of	NULL
G.	NULL
Freeman	NULL
(	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
)	NULL
.	NULL

The	NULL
anti-human	NULL
CD86	NULL
mAb	NULL
was	NULL
purchased	NULL
from	NULL
PharMingen	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Indirect	NULL
Immunofluorescent	NULL
Flow	NULL
Cytometry-Cells	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
primary	NULL
mAb	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
and	NULL
then	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
supplemented	NULL
with	NULL
2	NULL
%	NULL
FCS	NULL
and	NULL
0.02	NULL
%	NULL
NaN	NULL
,	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
20	NULL
ug/ml	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
goat	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
anti-mouse	NULL
antibody	NULL
(	NULL
Tago	NULL
,	NULL
Inc.	NULL
,	NULL
Burlingame	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
containing	NULL
2	NULL
%	NULL
FCS	NULL
and	NULL
0.02	NULL
%	NULL
NaN	NULL
,	NULL
,	NULL
resuspended	NULL
in	NULL
propidium	NULL
iodide	NULL
(	NULL
5-10	NULL
ug/ml	NULL
;	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Dead	NULL
cells	NULL
were	NULL
excluded	NULL
by	NULL
propidium	NULL
iodide	NULL
uptake	NULL
,	NULL
and	NULL
data	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
LYSYS	NULL
or	NULL
Cellquest	NULL
software	NULL
.	NULL

Measurement	NULL
of	NULL
IL-2	NULL
and	NULL
GM-CSF	NULL
Production-Human	NULL
purified	NULL
T	NULL
cells	NULL
or	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
plated	NULL
in	NULL
96-well	NULL
flat-bottomed	NULL
plates	NULL
at	NULL
2	NULL
X	NULL
10°/well	NULL
in	NULL
10	NULL
%	NULL
RPMI	NULL
with	NULL
the	NULL
anti-CD28	NULL
mAb	NULL
9.3	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
,	NULL
the	NULL
anti-CD3	NULL
mAb	NULL
OKT3	NULL
(	NULL
5	NULL
ng/ml	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
1.25	NULL
ng/ml	NULL
,	NULL
Sigma	NULL
)	NULL
,	NULL
parental	NULL
CHO	NULL
cells	NULL
or	NULL
CHO	NULL
cells	NULL
transfected	NULL
with	NULL
either	NULL
CD80	NULL
or	NULL
CD86	NULL
(	NULL
2	NULL
x	NULL
10*/Awell	NULL
)	NULL
,	NULL
as	NULL
indicated	NULL
,	NULL
in	NULL
200-pl	NULL
total	NULL
volume	NULL
.	NULL

Following	NULL
a	NULL
24	NULL
h	NULL
incubation	NULL
at	NULL
37°C	NULL
,	NULL
cell	NULL
culture	NULL
supernatants	NULL
were	NULL
collected	NULL
,	NULL
frozen	NULL
,	NULL
thawed	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
or	NULL
GM-CSF	NULL
by	NULL
their	NULL
ability	NULL
to	NULL
support	NULL
the	NULL
proliferation	NULL
of	NULL
an	NULL
IL-2-dependent	NULL
T-cell	NULL
line	NULL
CTLL-20	NULL
(	NULL
28	NULL
)	NULL
or	NULL
BaF/3	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
the	NULL
human	NULL
GM-CSF	NULL
receptor	NULL
(	NULL
24	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Proliferation	NULL
of	NULL
either	NULL
the	NULL
CTLL-20	NULL
cells	NULL
or	NULL
the	NULL
transfected	NULL
BaF/3	NULL
cells	NULL
was	NULL
assessed	NULL
by	NULL
the	NULL
incorporation	NULL
of	NULL
(	NULL
NEN	NULL
Life	NULL
Science	NULL
Products	NULL
)	NULL
after	NULL
a	NULL
6-h	NULL
pulse	NULL
following	NULL
an	NULL
18-h	NULL
incu-bation	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
units/ml	NULL
IL-2	NULL
or	NULL
GM-CSF	NULL
and	NULL
were	NULL
determined	NULL
by	NULL
extrapolation	NULL
to	NULL
standard	NULL
dilution	NULL
curves	NULL
using	NULL
human	NULL
recombinant	NULL
IL-2	NULL
(	NULL
Hoffmann-La	NULL
Roche	NULL
)	NULL
or	NULL
recombinant	NULL
GM-CSF	NULL
(	NULL
Ge-netics	NULL
Institute	NULL
,	NULL
Boston	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Transient	NULL
Transfection	NULL
and	NULL
Luciferase	NULL
Assay-Jurkat	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
a	NULL
reporter	NULL
plasmid	NULL
pSxNFAT-lue	NULL
(	NULL
25	NULL
)	NULL
,	NULL
carrying	NULL
the	NULL
luciferase	NULL
gene	NULL
driven	NULL
by	NULL
three	NULL
tandem	NULL
repeats	NULL
of	NULL
the	NULL
distal	NULL
NFAT	NULL
sequences	NULL
derived	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
electroporated	NULL
at	NULL
250	NULL
V	NULL
,	NULL
800	NULL
micro-farads	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

After	NULL
electroporation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
transferred	NULL
to	NULL
10	NULL
%	NULL
RPMI	NULL
and	NULL
incubated	NULL
at	NULL
37	NULL
°C	NULL
for	NULL
12	NULL
h.	NULL
Transfected	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
or	NULL
CHO-CD86	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
200	NULL
ng/ml	NULL
)	NULL
or	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
plus	NULL
ionomycin	NULL
(	NULL
2	NULL
uM	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
prepared	NULL
using	NULL
the	NULL
Enhanced	NULL
Luciferase	NULL
Kit	NULL
(	NULL
Analytic	NULL
Luminescent	NULL
Laboratory	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
relative	NULL
luciferase	NULL
units	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
stimulation	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
.	NULL

Cell	NULL
Stimulation	NULL
and	NULL
Immunoprecipitation-Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
cold	NULL
Buffer	NULL
A	NULL
(	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
and	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
)	NULL
.	NULL

Human	NULL
purified	NULL
T	NULL
cells	NULL
or	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
Buffer	NULL
A	NULL
,	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
with	NULL
parental	NULL
or	NULL
transfected	NULL
CHO	NULL
cells	NULL
,	NULL
anti-CD28	NULL
mAb	NULL
9.3	NULL
,	NULL
or	NULL
anti-CD8	NULL
mAb	NULL
OKT3	NULL
,	NULL
and	NULL
then	NULL
warmed	NULL
to	NULL
87	NULL
°C	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
cold	NULL
Buffer	NULL
A	NULL
containing	NULL
1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
lysed	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
cold	NULL
lysis	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
25	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
100	NULL
ug/ml	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
10	NULL
ug/ml	NULL
aprotinin	NULL
)	NULL
.	NULL

Detergent	NULL
extracts	NULL
were	NULL
clarified	NULL
by	NULL
centrifugation	NULL
at	NULL
14,000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

The	NULL
resulting	NULL
supernatants	NULL
were	NULL
harvested	NULL
and	NULL
used	NULL
for	NULL
immunoprecipitations	NULL
.	NULL

For	NULL
immunoprecipitation	NULL
,	NULL
cellular	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
antisera	NULL
and	NULL
25	NULL
ul	NULL
of	NULL
protein	NULL
A-agarose	NULL
for	NULL
at	NULL
least	NULL
2	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
after	NULL
which	NULL
the	NULL
resin	NULL
was	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
lysis	NULL
buffer	NULL
.	NULL

For	NULL
experiments	NULL
examining	NULL
the	NULL
association	NULL
of	NULL
CD28	NULL
with	NULL
phosphoinositide	NULL
3-kinase	NULL
(	NULL
PI8-K	NULL
)	NULL
,	NULL
the	NULL
immunoprecipitates	NULL
were	NULL
further	NULL
washed	NULL
twice	NULL
with	NULL
Buffer	NULL
B	NULL
(	NULL
0.5	NULL
M	NULL
LiCl	NULL
,	NULL
100	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
2	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
10	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
)	NULL
and	NULL
twice	NULL
with	NULL
Buffer	NULL
C	NULL
(	NULL
100	NULL
mM	NULL
NaCl	NULL
,	NULL
25	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
2	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
10	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
)	NULL
.	NULL

In	NULL
peptide	NULL
competition	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
3118	NULL
a	NULL
CD80	NULL
mAb	NULL
a	NULL
CD86	NULL
mAb	NULL
x	NULL
|	NULL
o	NULL
<	NULL
O	NULL
T	NULL
O	NULL
6	NULL
Tm	NULL
TIT	NULL
fe	NULL
!	NULL

€	NULL
3	NULL
Z	NULL
g	NULL
==	NULL
o	NULL
®	NULL
9	NULL
O	NULL
0	NULL
I	NULL
3	NULL
0	NULL
S	NULL
8	NULL
]	NULL
CC	NULL
el	NULL
&	NULL
[	NULL
as	NULL
Q	NULL
O	NULL
I	NULL
O	NULL
Log	NULL
Fluorescence	NULL
Intensity	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

CD80	NULL
and	NULL
CD86	NULL
expression	NULL
on	NULL
transfected	NULL
CHO	NULL
cells	NULL
.	NULL

CHO	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
the	NULL
murine	NULL
anti-human	NULL
CD80	NULL
mAb	NULL
183	NULL
(	NULL
1:200	NULL
dilution	NULL
)	NULL
,	NULL
the	NULL
murine	NULL
anti-human	NULL
CD86	NULL
mAb	NULL
IT2.2	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
,	NULL
or	NULL
diluent	NULL
alone	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Samples	NULL
were	NULL
washed	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
goat	NULL
anti-mouse	NULL
(	NULL
20	NULL
ug/ml	NULL
)	NULL
for	NULL
an	NULL
additional	NULL
20	NULL
min	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
propidium	NULL
iodide	NULL
(	NULL
5-10	NULL
ug/ml	NULL
)	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
Becton	NULL
Dickinson	NULL
FACscan	NULL
.	NULL

2000	NULL
events	NULL
were	NULL
collected	NULL
,	NULL
and	NULL
dead	NULL
cells	NULL
were	NULL
excluded	NULL
from	NULL
analysis	NULL
by	NULL
propidium	NULL
iodide	NULL
uptake	NULL
.	NULL

studies	NULL
,	NULL
5	NULL
uM	NULL
of	NULL
HSDYMNMTPRR	NULL
or	NULL
HSD-phospho-YMNMTPRR	NULL
peptides	NULL
(	NULL
pYMNM	NULL
)	NULL
(	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
S.	NULL
Shoelson	NULL
,	NULL
Joslin	NULL
Diabetes	NULL
Center	NULL
,	NULL
Boston	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
lysates	NULL
prior	NULL
to	NULL
incubation	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
.	NULL

Immunoprecipitated	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
through	NULL
SDS-polyacrylamide	NULL
gels	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
(	NULL
Protogel	NULL
,	NULL
National	NULL
Diagnostics	NULL
,	NULL
Atlanta	NULL
,	NULL
GA	NULL
)	NULL
transferred	NULL
to	NULL
polyvinylidene	NULL
difluoride	NULL
(	NULL
PVDF	NULL
)	NULL
membranes	NULL
(	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
immunoblotted	NULL
with	NULL
the	NULL
antibody	NULL
of	NULL
interest	NULL
,	NULL
and	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
)	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Deglycosylation	NULL
and	NULL
precipitation	NULL
of	NULL
the	NULL
CD28	NULL
polypeptide	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
26	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
the	NULL
immunoprecipitates	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
RIPA	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
0.5	NULL
%	NULL
sodium	NULL
deoxycholate	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
50	NULL
mM	NULL
Tris-Cl	NULL
,	NULL
pH	NULL
8	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
10	NULL
ug/ml	NULL
aprotinin	NULL
)	NULL
,	NULL
twice	NULL
with	NULL
RIPA	NULL
buffer	NULL
containing	NULL
1	NULL
M	NULL
NaCl	NULL
,	NULL
twice	NULL
more	NULL
with	NULL
RIPA	NULL
buffer	NULL
,	NULL
and	NULL
once	NULL
with	NULL
Buffer	NULL
D	NULL
(	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
50	NULL
mM	NULL
Tris-Cl	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
100	NULL
ug/ml	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
,	NULL
10	NULL
pg/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
10	NULL
ug/ml	NULL
aprotinin	NULL
)	NULL
.	NULL

The	NULL
immunoprecipitated	NULL
proteins	NULL
were	NULL
denatured	NULL
by	NULL
boiling	NULL
for	NULL
10	NULL
min	NULL
in	NULL
a	NULL
solution	NULL
of	NULL
0.5	NULL
%	NULL
SDS	NULL
and	NULL
1	NULL
%	NULL
B-mercaptoethanol	NULL
and	NULL
then	NULL
adjusted	NULL
to	NULL
50	NULL
mM	NULL
sodium	NULL
phosphate	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
and	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
1,000	NULL
units	NULL
of	NULL
peptide	NULL
:	NULL
N-glycosidase	NULL
F	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
an	NULL
enzyme	NULL
that	NULL
hydrolyzes	NULL
N-glycan	NULL
chains	NULL
from	NULL
proteins	NULL
.	NULL

Deglycosylated	NULL
proteins	NULL
were	NULL
separated	NULL
on	NULL
10.5	NULL
%	NULL
SDS-PAGE	NULL
gels	NULL
and	NULL
visualized	NULL
by	NULL
immunoblotting	NULL
as	NULL
described	NULL
above	NULL
.	NULL

RESULTS	NULL
Both	NULL
CD80	NULL
and	NULL
CD86	NULL
Costimulate	NULL
T	NULL
cell	NULL
cytokine	NULL
Production	NULL
and	NULL
NFAT-mediated	NULL
Transcriptional	NULL
Activation-We	NULL
used	NULL
CHO	NULL
cells	NULL
transfected	NULL
with	NULL
either	NULL
vector	NULL
alone	NULL
(	NULL
CHO-Mock	NULL
)	NULL
or	NULL
the	NULL
cDNA	NULL
encoding	NULL
either	NULL
human	NULL
CD80	NULL
(	NULL
CHO-CD80	NULL
)	NULL
or	NULL
human	NULL
CD86	NULL
(	NULL
CHO-CD86	NULL
)	NULL
to	NULL
compare	NULL
the	NULL
intracellular	NULL
signals	NULL
triggered	NULL
by	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
natural	NULL
ligands	NULL
of	NULL
CD28	NULL
.	NULL

The	NULL
transfected	NULL
CHO	NULL
cells	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
had	NULL
expressed	NULL
comparable	NULL
surface	NULL
CD80	NULL
and	NULL
CD86	NULL
as	NULL
detected	NULL
by	NULL
Differential	NULL
Signaling	NULL
through	NULL
CD28	NULL
by	NULL
Ligands	NULL
CD80	NULL
and	NULL
CD86	NULL
TaBLE	NULL
I	NULL
IL-2	NULL
production	NULL
after	NULL
costimulation	NULL
with	NULL
CHO	NULL
cells	NULL
expressing	NULL
CD80	NULL
or	NULL
CD86	NULL
Human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
or	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
2	NULL
X	NULL
10°	NULL
cells/well	NULL
,	NULL
were	NULL
cultured	NULL
with	NULL
2	NULL
X	NULL
10	NULL
%	NULL
CHO/well	NULL
,	NULL
1.25	NULL
ng/ml	NULL
PMA	NULL
,	NULL
100	NULL
ng/ml	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Production	NULL
of	NULL
IL-2	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
and	NULL
is	NULL
expressed	NULL
as	NULL
units/ml	NULL
by	NULL
comparison	NULL
with	NULL
a	NULL
standard	NULL
curve	NULL
generated	NULL
with	NULL
recombinant	NULL
human	NULL
IL-2	NULL
.	NULL

A	NULL
representative	NULL
assay	NULL
from	NULL
a	NULL
total	NULL
of	NULL
three	NULL
assays	NULL
performed	NULL
with	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
mean	NULL
*	NULL
S.D	NULL
.	NULL

IL-2	NULL
production	NULL
of	NULL
three	NULL
independent	NULL
assays	NULL
performed	NULL
using	NULL
Jurkat	NULL
T	NULL
cells	NULL
is	NULL
shown	NULL
.	NULL

Human	NULL
peripheral	NULL
Jurkat	NULL
T	NULL
cells	NULL
cells	NULL
-PMA	NULL
+PMA	NULL
-PMA	NULL
+PMA	NULL
Media	NULL
<	NULL
0.5	NULL
2.7	NULL
<	NULL
0.5	NULL
<	NULL
0.5	NULL
Anti-CD28	NULL
mAb	NULL
<	NULL
0.5	NULL
170	NULL
<	NULL
0.5	NULL
19	NULL
+	NULL
16	NULL
CHO-Mock	NULL
<	NULL
0.5	NULL
1.4	NULL
<	NULL
0.5	NULL
<	NULL
0.5	NULL
CHO-CD80	NULL
<	NULL
0.5	NULL
370	NULL
<	NULL
0.5	NULL
1.6	NULL
+	NULL
0.8	NULL
CHO-CD86	NULL
<	NULL
0.5	NULL
50	NULL
<	NULL
0.5	NULL
2.2	NULL
+	NULL
1.5	NULL
indirect	NULL
immunofluorescence	NULL
using	NULL
either	NULL
anti-CD80	NULL
or	NULL
anti-CD86	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
CHO-CD80	NULL
cells	NULL
expressed	NULL
CD80	NULL
but	NULL
failed	NULL
to	NULL
express	NULL
CD86	NULL
,	NULL
and	NULL
CHO-CD86	NULL
cells	NULL
expressed	NULL
CD86	NULL
but	NULL
did	NULL
not	NULL
express	NULL
CD80	NULL
;	NULL
CHO-Mock	NULL
cells	NULL
,	NULL
transfected	NULL
with	NULL
the	NULL
vector	NULL
encoding	NULL
neomycin	NULL
resistance	NULL
(	NULL
G418	NULL
``	NULL
)	NULL
alone	NULL
,	NULL
expressed	NULL
neither	NULL
B7	NULL
family	NULL
member	NULL
.	NULL

Both	NULL
CD80	NULL
and	NULL
CD86	NULL
are	NULL
capable	NULL
of	NULL
costimulating	NULL
a	NULL
number	NULL
of	NULL
T	NULL
cell	NULL
functions	NULL
including	NULL
cytokine	NULL
production	NULL
and	NULL
proliferation	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

27	NULL
)	NULL
.	NULL

Resting	NULL
,	NULL
human	NULL
purified	NULL
CD4*	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
and	NULL
CD3	NULL
*	NULL
Jurkat	NULL
cells	NULL
were	NULL
assayed	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
produce	NULL
IL-2	NULL
and	NULL
GM-CSF	NULL
in	NULL
response	NULL
to	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
or	NULL
CHO-CD86	NULL
cells	NULL
or	NULL
to	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
phorbol	NULL
ester	NULL
PMA	NULL
.	NULL

T	NULL
cells	NULL
and	NULL
Jurkat	NULL
cells	NULL
both	NULL
produced	NULL
IL-2	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
and	NULL
T	NULL
cells	NULL
produced	NULL
GM-CSF	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
in	NULL
response	NULL
to	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
either	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
CHO-CD80	NULL
,	NULL
or	NULL
CHO-CD86	NULL
cells	NULL
.	NULL

No	NULL
IL-2	NULL
was	NULL
produced	NULL
after	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
or	NULL
mock	NULL
or	NULL
transfected	NULL
CHO	NULL
cells	NULL
alone	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
costimulation	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
with	NULL
CHO-CD80	NULL
elicited	NULL
more	NULL
IL-2	NULL
than	NULL
did	NULL
costimulation	NULL
with	NULL
CHO-CD86	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
,	NULL
whereas	NULL
there	NULL
were	NULL
no	NULL
reproducible	NULL
,	NULL
quantitative	NULL
differences	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
IL-2	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
produced	NULL
by	NULL
Jurkat	NULL
cells	NULL
or	NULL
GM-CSF	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
produced	NULL
by	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
after	NULL
CHO-CD80	NULL
or	NULL
CHO-CD86	NULL
stimulation	NULL
.	NULL

Cytokine	NULL
production	NULL
is	NULL
a	NULL
somewhat	NULL
distal	NULL
readout	NULL
of	NULL
CD28-dependent	NULL
stimulation	NULL
;	NULL
to	NULL
analyze	NULL
a	NULL
more	NULL
proximal	NULL
readout	NULL
of	NULL
CD28-dependent	NULL
stimulation	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
relative	NULL
abilities	NULL
of	NULL
the	NULL
two	NULL
ligands	NULL
to	NULL
costimulate	NULL
NFAT-dependent	NULL
transcriptional	NULL
activation	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
reporter	NULL
plasmid	NULL
carrying	NULL
the	NULL
luciferase	NULL
gene	NULL
driven	NULL
by	NULL
three	NULL
tandem	NULL
repeats	NULL
of	NULL
the	NULL
distal	NULL
NFAT	NULL
sequences	NULL
derived	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
stimulated	NULL
with	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
or	NULL
CHO-CD86	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CD3	NULL
mAb	NULL
or	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

NFAT-mediated	NULL
transcriptional	NULL
activity	NULL
was	NULL
induced	NULL
by	NULL
CHO-CD80	NULL
,	NULL
and	NULL
more	NULL
so	NULL
by	NULL
CHO-CD86	NULL
,	NULL
whereas	NULL
CHO-Mock	NULL
induced	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
activity	NULL
as	NULL
anti-CD3	NULL
mAb	NULL
alone	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
a	NULL
blocking	NULL
CD28	NULL
mAb	NULL
to	NULL
the	NULL
stimulations	NULL
abrogated	NULL
both	NULL
CD80-	NULL
and	NULL
CD86-dependent	NULL
NFAT-mediated	NULL
transcriptional	NULL
activation	NULL
,	NULL
confirming	NULL
that	NULL
both	NULL
CD80	NULL
and	NULL
CD86	NULL
were	NULL
signaling	NULL
through	NULL
CD28	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Stimulation	NULL
with	NULL
CD80	NULL
or	NULL
CD86	NULL
Induces	NULL
the	NULL
in	NULL
Vivo	NULL
Tyrosine	NULL
Phosphorylation	NULL
of	NULL
Several	NULL
T	NULL
Cell	NULL
Proteins	NULL
Including	NULL
CBL	NULL
and	NULL
VAV-Having	NULL
established	NULL
,	NULL
in	NULL
this	NULL
system	NULL
,	NULL
that	NULL
the	NULL
CHO-CD80	NULL
and	NULL
CHO-CD86	NULL
cells	NULL
were	NULL
both	NULL
competent	NULL
to	NULL
costimulate	NULL
cytokine	NULL
production	NULL
as	NULL
well	NULL
as	NULL
NFAT-mediated	NULL
transcriptional	NULL
activation	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
early	NULL
signaling	NULL
events	NULL
induced	NULL
by	NULL
anti-CD28	NULL
mAb	NULL
with	NULL
those	NULL
induced	NULL
by	NULL
each	NULL
of	NULL
the	NULL
two	NULL
natural	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Differential	NULL
Signaling	NULL
through	NULL
CD28	NULL
by	NULL
Ligands	NULL
CD80	NULL
and	NULL
CD86	NULL
3119	NULL
TaBLE	NULL
II	NULL
GM-CSF	NULL
production	NULL
after	NULL
costimulation	NULL
with	NULL
CHO	NULL
cells	NULL
expressing	NULL
CD80	NULL
or	NULL
CD86	NULL
Human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
,	NULL
2	NULL
X	NULL
10°	NULL
cells/well	NULL
,	NULL
were	NULL
cultured	NULL
with	NULL
2	NULL
X	NULL
10°	NULL
transfected	NULL
CHO	NULL
cells/well	NULL
or	NULL
100	NULL
ng/ml	NULL
anti-CD28	NULL
mAb	NULL
with	NULL
or	NULL
without	NULL
1.25	NULL
ng/ml	NULL
PMA	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Production	NULL
of	NULL
GM-CSF	NULL
(	NULL
units/	NULL
ml	NULL
)	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
by	NULL
comparison	NULL
with	NULL
a	NULL
standard	NULL
curve	NULL
generated	NULL
using	NULL
recombinant	NULL
human	NULL
GM-CSF	NULL
.	NULL

A	NULL
representative	NULL
assay	NULL
from	NULL
a	NULL
total	NULL
of	NULL
three	NULL
assays	NULL
performed	NULL
is	NULL
shown	NULL
.	NULL

GM-CSF	NULL
produced	NULL
-PMA	NULL
+PMA	NULL
units/ml	NULL
Media	NULL
<	NULL
0.9	NULL
58.4	NULL
Anti-CD28	NULL
mAb	NULL
<	NULL
0.9	NULL
800	NULL
CHO-Mock	NULL
8.1	NULL
290	NULL
CHO-CD80	NULL
2.7	NULL
1980	NULL
CHO-CD86	NULL
2.8	NULL
1250	NULL
ligands	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
either	NULL
mock	NULL
or	NULL
transfected	NULL
CHO	NULL
cells	NULL
or	NULL
,	NULL
for	NULL
comparison	NULL
,	NULL
anti-CD28	NULL
or	NULL
anti-CD3	NULL
mAb	NULL
for	NULL
5	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Analysis	NULL
of	NULL
post-nuclear	NULL
lysates	NULL
by	NULL
phosphotyrosine	NULL
immunoblotting	NULL
yielded	NULL
no	NULL
significant	NULL
differences	NULL
between	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
and	NULL
CHO-CD86	NULL
cell	NULL
stimulations	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
enhance	NULL
the	NULL
detection	NULL
of	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
,	NULL
anti-phosphotyrosine	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
from	NULL
stimulated	NULL
Jurkat	NULL
cell	NULL
ly-sates	NULL
,	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
PVDF	NULL
mem-branes	NULL
,	NULL
and	NULL
detected	NULL
by	NULL
anti-phosphotyrosine	NULL
Western	NULL
blot	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
a	NULL
distinct	NULL
pattern	NULL
of	NULL
tyrosine	NULL
phosphorylated	NULL
proteins	NULL
was	NULL
detected	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Increases	NULL
in	NULL
tyrosyl-phosphorylated	NULL
proteins	NULL
were	NULL
also	NULL
seen	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
soluble	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
cross-linked	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
anti-CD28	NULL
mAb	NULL
9.3	NULL
.	NULL

There	NULL
was	NULL
an	NULL
increase	NULL
in	NULL
detection	NULL
of	NULL
both	NULL
an	NULL
~95-kDa	NULL
protein	NULL
(	NULL
indicated	NULL
by	NULL
the	NULL
open	NULL
arrowhead	NULL
)	NULL
after	NULL
anti-CD3	NULL
mAb	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
and	NULL
an	NULL
~115-120-kDa	NULL
protein	NULL
(	NULL
indicated	NULL
by	NULL
the	NULL
solid	NULL
arrowhead	NULL
)	NULL
in	NULL
both	NULL
the	NULL
anti-CD3	NULL
mAb	NULL
and	NULL
the	NULL
anti-CD28	NULL
mAb-stimulated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lanes	NULL
5-7	NULL
)	NULL
.	NULL

The	NULL
phosphorylation	NULL
of	NULL
the	NULL
~95-kDa	NULL
band	NULL
was	NULL
preferentially	NULL
enhanced	NULL
after	NULL
stimulation	NULL
with	NULL
CHO-CD80	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
when	NULL
compared	NULL
with	NULL
CHO-CD86-	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
or	NULL
CHO-Mock	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
-treated	NULL
cells	NULL
.	NULL

The	NULL
CHO	NULL
cells	NULL
alone	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Jurkat	NULL
cells	NULL
,	NULL
contained	NULL
few	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
lane	NULL
I	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
purified	NULL
human	NULL
peripheral	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Characteristic	NULL
increases	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
were	NULL
observed	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
and	NULL
with	NULL
soluble	NULL
or	NULL
cross-linked	NULL
anti-CD28	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lane	NULL
6-8	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
also	NULL
observed	NULL
following	NULL
stimulation	NULL
with	NULL
CHO-CD80	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
CHO-CD86	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

These	NULL
differences	NULL
were	NULL
subtle	NULL
,	NULL
however	NULL
,	NULL
and	NULL
therefore	NULL
the	NULL
ability	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
to	NULL
induce	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
specific	NULL
signaling	NULL
proteins	NULL
was	NULL
examined	NULL
.	NULL

VAV	NULL
is	NULL
a	NULL
95-kDa	NULL
protein	NULL
expressed	NULL
exclusively	NULL
in	NULL
hematopoietic	NULL
cells	NULL
that	NULL
is	NULL
rapidly	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
after	NULL
ligation	NULL
of	NULL
the	NULL
TeR-CD3	NULL
complex	NULL
(	NULL
28	NULL
)	NULL
or	NULL
CD28	NULL
(	NULL
29	NULL
)	NULL
.	NULL

This	NULL
tyrosine	NULL
phosphorylation	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
VAV	NULL
as	NULL
an	NULL
exchange	NULL
factor	NULL
for	NULL
Rac-l1	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
either	NULL
CHO-CD80	NULL
or	NULL
CHO-CD86	NULL
induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
VAV	NULL
that	NULL
was	NULL
detectable	NULL
by	NULL
30	NULL
s	NULL
and	NULL
appeared	NULL
to	NULL
decrease	NULL
by	NULL
10	NULL
min	NULL
of	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Comparable	NULL
activation-dependent	NULL
changes	NULL
in	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
VAV	NULL
after	NULL
CD80	NULL
and	NULL
CD86	NULL
stimulation	NULL
were	NULL
also	NULL
observed	NULL
in	NULL
peripheral	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
although	NULL
maximal	NULL
signals	NULL
were	NULL
not	NULL
as	NULL
high	NULL
.	NULL

CBL	NULL
is	NULL
an	NULL
~120-kDa	NULL
protein	NULL
that	NULL
is	NULL
rapidly	NULL
tyrosine-phosphorylated	NULL
in	NULL
response	NULL
to	NULL
TeR	NULL
(	NULL
31	NULL
)	NULL
and	NULL
FeyR	NULL
stimulation	NULL
(	NULL
32	NULL
)	NULL
.	NULL

125	NULL
anti-CD3	NULL
mAb	NULL
CHO-Mock	NULL
+	NULL
anti-CD3	NULL
mAb	NULL
CHO-CD80	NULL
+	NULL
anti-CD3	NULL
mAb	NULL
4	NULL
0	NULL
QO	NULL
I	NULL
CHO-CD86	NULL
+	NULL
anti-CD3	NULL
mAb	NULL
75	NULL
-I	NULL
Percent	NULL
of	NULL
PMA	NULL
+	NULL
Ionomycin	NULL
Stimulation	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Costimulation	NULL
with	NULL
CD80	NULL
or	NULL
CD86	NULL
induces	NULL
NFAT-mediated	NULL
transcriptional	NULL
activity	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
transiently	NULL
transfected	NULL
with	NULL
an	NULL
NFAT-luciferase	NULL
reporter	NULL
plasmid	NULL
were	NULL
stimulated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
soluble	NULL
anti-CD3	NULL
mAb	NULL
alone	NULL
(	NULL
200	NULL
ng/ml	NULL
)	NULL
(	NULL
dashed	NULL
bar	NULL
)	NULL
or	NULL
with	NULL
soluble	NULL
anti-CD3	NULL
mAb	NULL
plus	NULL
CHO-Mock	NULL
(	NULL
shaded	NULL
bar	NULL
)	NULL
,	NULL
CHO-CD80	NULL
(	NULL
open	NULL
bar	NULL
)	NULL
,	NULL
or	NULL
CHO-CD86	NULL
(	NULL
solid	NULL
bar	NULL
)	NULL
or	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
plus	NULL
ionomycin	NULL
(	NULL
2	NULL
uM	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
prepared	NULL
using	NULL
the	NULL
Enhanced	NULL
Luciferase	NULL
Kit	NULL
(	NULL
Analytic	NULL
Luminescent	NULL
Laboratory	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
relative	NULL
luciferase	NULL
units	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
activity	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
and	NULL
represent	NULL
the	NULL
mean	NULL
plus	NULL
S.D	NULL
.	NULL

of	NULL
three	NULL
separate	NULL
assays	NULL
.	NULL

CBL	NULL
is	NULL
an	NULL
intracellular	NULL
docking	NULL
protein	NULL
that	NULL
associates	NULL
with	NULL
a	NULL
number	NULL
of	NULL
SH2-	NULL
and	NULL
SH3-containing	NULL
proteins	NULL
including	NULL
p59	NULL
``	NULL
PI3-K	NULL
,	NULL
Zap-70	NULL
,	NULL
and	NULL
the	NULL
adapter	NULL
protein	NULL
Grb2	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

33	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
for	NULL
5	NULL
min	NULL
with	NULL
CD80	NULL
,	NULL
CD86	NULL
,	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
and	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
anti-CD3	NULL
mAb	NULL
all	NULL
induced	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CBL	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
CD80	NULL
and	NULL
CD86	NULL
share	NULL
the	NULL
ability	NULL
to	NULL
induce	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
several	NULL
intracellular	NULL
signaling	NULL
proteins	NULL
,	NULL
including	NULL
CBL	NULL
and	NULL
VAV	NULL
.	NULL

CD80	NULL
and	NULL
CD86	NULL
Differ	NULL
in	NULL
Their	NULL
Ability	NULL
to	NULL
Induce	NULL
Tyrosine	NULL
Phosphorylation	NULL
of	NULL
PLC-y1	NULL
and	NULL
CD28-The	NULL
ability	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
to	NULL
induce	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLC-y1	NULL
differed	NULL
.	NULL

Anti-phosphotyrosine	NULL
immunoprecipitates	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
CHO-Mock	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
CHO-CD80	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
CHO-CD86	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
mAb	NULL
to	NULL
CD3	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
mAb	NULL
to	NULL
CD28	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
or	NULL
left	NULL
unstimulated	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
for	NULL
5	NULL
min	NULL
were	NULL
probed	NULL
by	NULL
anti-PLC-y1	NULL
antisera	NULL
.	NULL

Stimulation	NULL
with	NULL
CHO-CD80	NULL
induced	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
PLC-y1	NULL
stimulation	NULL
,	NULL
whereas	NULL
stimulation	NULL
with	NULL
CHO-CD86	NULL
in-duced	NULL
,	NULL
like	NULL
CHO-Mock	NULL
treatment	NULL
,	NULL
a	NULL
much	NULL
smaller	NULL
increase	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
CD4	NULL
*	NULL
peripheral	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
CD80	NULL
and	NULL
CD86	NULL
differed	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
induce	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLC-y1	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
CD4*	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
developed	NULL
a	NULL
deglycosylation	NULL
procedure	NULL
that	NULL
allowed	NULL
the	NULL
detection	NULL
and	NULL
identification	NULL
of	NULL
a	NULL
distinct	NULL
CD28	NULL
protein	NULL
band	NULL
,	NULL
facilitating	NULL
the	NULL
analysis	NULL
of	NULL
activation-dependent	NULL
changes	NULL
in	NULL
the	NULL
state	NULL
of	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
itself	NULL
(	NULL
26	NULL
)	NULL
.	NULL

We	NULL
have	NULL
reported	NULL
that	NULL
anti-CD28	NULL
mAb	NULL
stimulation	NULL
led	NULL
to	NULL
the	NULL
Lck-dependent	NULL
,	NULL
in	NULL
vivo	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
on	NULL
tyrosine	NULL
as	NULL
detected	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
(	NULL
26	NULL
)	NULL
.	NULL

We	NULL
used	NULL
this	NULL
technique	NULL
to	NULL
compare	NULL
the	NULL
ability	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
to	NULL
induce	NULL
the	NULL
in	NULL
vivo	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
min	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
or	NULL
mock-	NULL
,	NULL
CD80-	NULL
,	NULL
or	NULL
CD86-transfected	NULL
CHO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

Stringently	NULL
washed	NULL
anti-CD28	NULL
immunoprecipitates	NULL
were	NULL
treated	NULL
with	NULL
peptide	NULL
:	NULL
N-glycosidase	NULL
F	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
3120	NULL
Differential	NULL
Signaling	NULL
through	NULL
CD28	NULL
by	NULL
Ligands	NULL
CD80	NULL
and	NULL
CD86	NULL
+	NULL
Jurkat	NULL
[	NULL
OI	NULL
&	NULL
CD28	NULL
mAb	NULL
+	NULL
RAM	NULL
CHO-CD80	NULL
CHO-Mock	NULL
CHO-CD8O	NULL
CHO-CD86	NULL
«	NULL
CD28	NULL
mAb	NULL
«	NULL
CD3	NULL
mAb	NULL
No	NULL
stimulation	NULL
217-	NULL
111+	NULL
72-	NULL
iii	NULL
&	NULL
at	NULL
dik	NULL
Cee	NULL
se	NULL
t=	NULL
44	NULL
«	NULL
ils	NULL
28	NULL
-18-	NULL
=E	NULL
15	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
+	NULL
T	NULL
cells	NULL
[	NULL
--	NULL
-a	NULL
<	NULL
C	NULL
cC	NULL
c	NULL
+	NULL
ceee	NULL
§	NULL
6	NULL
©	NULL
§§	NULL
<	NULL
F	NULL
g	NULL
a	NULL
3	NULL
0A	NULL
A	NULL
2	NULL
E	NULL
a	NULL
m	NULL
a	NULL
aa	NULL
O	NULL
O	NULL
®	NULL
T	NULL
I	NULL
E	NULL
E	NULL
o	NULL
0	NULL
O	NULL
O	NULL
0	NULL
0	NULL
G	NULL
OZ	NULL
s	NULL
s	NULL
s	NULL
217-111-	NULL
-	NULL
e	NULL
28-	NULL
|y	NULL
TO	NULL
18-	NULL
wite	NULL
15-	NULL
|	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
in	NULL
Jurkat	NULL
(	NULL
A4	NULL
)	NULL
or	NULL
purified	NULL
peripheral	NULL
blood	NULL
(	NULL
B	NULL
)	NULL
human	NULL
T	NULL
cells	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
,	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
and	NULL
CHO-CD86	NULL
.	NULL

A	NULL
,	NULL
anti-phosphotyrosine	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
CHO-CD80	NULL
cells	NULL
alone	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
or	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
left	NULL
untreated	NULL
(	NULL
Zane	NULL
8	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
CHO-Mock	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
,	NULL
-CD80	NULL
(	NULL
Zane	NULL
3	NULL
)	NULL
,	NULL
-CD86	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
,	NULL
CHO	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
,	NULL
4	NULL
ug/ml	NULL
anti-CD28	NULL
mAb	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
10	NULL
pg/ml	NULL
rabbit	NULL
anti-mouse	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
or	NULL
with	NULL
6	NULL
ug/ml	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
Zane	NULL
7	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
followed	NULL
by	NULL
5	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Stimulations	NULL
were	NULL
stopped	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
cold	NULL
Buffer	NULL
A	NULL
containing	NULL
1	NULL
mM	NULL
Na	NULL
,	NULL
VO	NULL
,	NULL
;	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
Buffer	NULL
A/Na	NULL
,	NULL
VO	NULL
,	NULL
and	NULL
then	NULL
lysed	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
15	NULL
min	NULL
in	NULL
to	NULL
remove	NULL
N-linked	NULL
sugars	NULL
from	NULL
CD28	NULL
.	NULL

Stimulation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
CHO-CD80	NULL
cells	NULL
or	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
induced	NULL
the	NULL
in	NULL
vivo	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
parallel	NULL
treatments	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
CHO-CD86	NULL
failed	NULL
to	NULL
elicit	NULL
any	NULL
detectable	NULL
CD28	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

To	NULL
eliminate	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
difference	NULL
in	NULL
CD28	NULL
phosphorylation	NULL
after	NULL
CD80	NULL
and	NULL
CD86	NULL
stimulation	NULL
resulted	NULL
from	NULL
an	NULL
artifact	NULL
of	NULL
the	NULL
CHO-human	NULL
B7	NULL
transfectants	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
ability	NULL
of	NULL
murine	NULL
B7	NULL
family	NULL
members	NULL
to	NULL
induce	NULL
CD28	NULL
phosphorylation	NULL
in	NULL
murine	NULL
cells	NULL
and	NULL
found	NULL
that	NULL
CD80	NULL
but	NULL
not	NULL
CD86	NULL
induced	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
murine	NULL
CD28	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Time	NULL
course	NULL
studies	NULL
were	NULL
performed	NULL
to	NULL
determine	NULL
if	NULL
the	NULL
difference	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
to	NULL
induce	NULL
CD28	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
a	NULL
qualitative	NULL
or	NULL
a	NULL
kinetic	NULL
difference	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Robust	NULL
CD28	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
detected	NULL
at	NULL
5	NULL
min	NULL
and	NULL
was	NULL
still	NULL
detectable	NULL
at	NULL
30	NULL
min	NULL
following	NULL
ligation	NULL
by	NULL
the	NULL
ligand	NULL
CD80	NULL
;	NULL
in	NULL
striking	NULL
contrast	NULL
,	NULL
no	NULL
CD28	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
detected	NULL
following	NULL
CD86	NULL
ligation	NULL
at	NULL
any	NULL
time	NULL
point	NULL
analyzed	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

CD80	NULL
and	NULL
CD86	NULL
Differ	NULL
in	NULL
Their	NULL
Ability	NULL
to	NULL
Induce	NULL
the	NULL
Association	NULL
of	NULL
CD28	NULL
with	NULL
PI3	NULL
Kinase-Differential	NULL
protein	NULL
phosphorylation	NULL
is	NULL
one	NULL
mechanism	NULL
regulating	NULL
the	NULL
local	NULL
assembly	NULL
of	NULL
functional	NULL
protein	NULL
complexes	NULL
.	NULL

Given	NULL
the	NULL
dramatic	NULL
ligand-specific	NULL
differences	NULL
in	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
on	NULL
the	NULL
recruitment	NULL
of	NULL
intracellular	NULL
signaling	NULL
proteins	NULL
to	NULL
the	NULL
CD28	NULL
receptor	NULL
complex	NULL
.	NULL

Stimulation	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
lead	NULL
to	NULL
the	NULL
SH2-dependent	NULL
association	NULL
of	NULL
the	NULL
heterodimeric	NULL
p85/p110	NULL
PI3-K	NULL
with	NULL
the	NULL
-Tyr	NULL
(	NULL
P	NULL
)	NULL
``	NULL
``	NULL
``	NULL
-Met-Asn-Met-	NULL
sequence	NULL
in	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
CD28	NULL
(	NULL
34-37	NULL
)	NULL
.	NULL

There	NULL
is	NULL
a	NULL
concomitant	NULL
increase	NULL
in	NULL
PI3	NULL
lipid	NULL
kinase	NULL
activity	NULL
that	NULL
may	NULL
be	NULL
important	NULL
in	NULL
CD28	NULL
signaling	NULL
pathways	NULL
,	NULL
particularly	NULL
in	NULL
those	NULL
involved	NULL
in	NULL
the	NULL
prolongation	NULL
of	NULL
T	NULL
cell	NULL
survival	NULL
(	NULL
35	NULL
,	NULL
36	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Given	NULL
the	NULL
dramatic	NULL
difference	NULL
in	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
after	NULL
stimulation	NULL
with	NULL
CD80	NULL
versus	NULL
CD86	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
CD28	NULL
to	NULL
bind	NULL
PI3-K	NULL
as	NULL
an	NULL
in	NULL
vivo	NULL
functional	NULL
correlate	NULL
of	NULL
CD28	NULL
tyrosyl	NULL
phosphorylation	NULL
.	NULL

CD28	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
CHO-CD86	NULL
,	NULL
or	NULL
the	NULL
anti-CD28	NULL
mAb	NULL
;	NULL
coprecipitated	NULL
PI3-K	NULL
were	NULL
detected	NULL
using	NULL
an	NULL
antibody	NULL
directed	NULL
against	NULL
the	NULL
p85	NULL
subunit	NULL
of	NULL
PI3-K.	NULL
Stimulation	NULL
with	NULL
either	NULL
CD80	NULL
or	NULL
anti-CD28	NULL
mAb	NULL
induced	NULL
the	NULL
association	NULL
of	NULL
PI3-K	NULL
with	NULL
CD28	NULL
;	NULL
in	NULL
contrast	NULL
,	NULL
the	NULL
PI3-K/CD28	NULL
association	NULL
was	NULL
much	NULL
less	NULL
dramatic	NULL
following	NULL
CD86	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

This	NULL
association	NULL
was	NULL
evident	NULL
by	NULL
2	NULL
min	NULL
after	NULL
stimulation	NULL
with	NULL
CD80	NULL
and	NULL
continued	NULL
for	NULL
at	NULL
least	NULL
30	NULL
min	NULL
after	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
then	NULL
tested	NULL
the	NULL
ligand-specific	NULL
association	NULL
of	NULL
PI3-K	NULL
with	NULL
CD28	NULL
in	NULL
purified	NULL
CD4*	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
)	NULL
.	NULL

Stimulation	NULL
for	NULL
15	NULL
min	NULL
with	NULL
CD80	NULL
and	NULL
mAb	NULL
to	NULL
CD28	NULL
induced	NULL
the	NULL
association	NULL
of	NULL
PI3-K	NULL
with	NULL
CD28	NULL
,	NULL
whereas	NULL
CD86	NULL
did	NULL
so	NULL
to	NULL
a	NULL
much	NULL
lesser	NULL
extent	NULL
.	NULL

The	NULL
time	NULL
course	NULL
of	NULL
PI3-K	NULL
association	NULL
appeared	NULL
to	NULL
be	NULL
slightly	NULL
different	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
than	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
in	NULL
that	NULL
induction	NULL
of	NULL
PIS-K	NULL
association	NULL
at	NULL
15	NULL
min	NULL
exceeded	NULL
that	NULL
at	NULL
5	NULL
min	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

1	NULL
ml	NULL
of	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
lysis	NULL
buffer	NULL
.	NULL

Lysates	NULL
were	NULL
clarified	NULL
by	NULL
centrifugation	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
precoupled	NULL
to	NULL
agarose	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Lysates	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
through	NULL
a	NULL
6-15	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
then	NULL
transferred	NULL
to	NULL
PVDF	NULL
membranes	NULL
.	NULL

Tyrosine-phosphorylated	NULL
proteins	NULL
were	NULL
detected	NULL
with	NULL
anti-phosphotyrosine	NULL
antibody	NULL
(	NULL
RC20	NULL
1:2500	NULL
dilution	NULL
)	NULL
for	NULL
2	NULL
h	NULL
,	NULL
and	NULL
the	NULL
proteins	NULL
were	NULL
visualized	NULL
by	NULL
ECL	NULL
.	NULL

The	NULL
migration	NULL
of	NULL
molecular	NULL
mass	NULL
markers	NULL
are	NULL
indicated	NULL
.	NULL

B	NULL
,	NULL
anti-phosphotyrosine	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
2	NULL
X	NULL
10	NULL
``	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
as	NULL
in	NULL
A.	NULL
Lysates	NULL
were	NULL
prepared	NULL
from	NULL
CHO-CD80	NULL
cells	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
from	NULL
unstimulated	NULL
T	NULL
cells	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
or	NULL
from	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
CHO-Mock	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
,	NULL
CHO-CD80	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
CHO-CD86	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
,	NULL
anti-CD28	NULL
mAb	NULL
(	NULL
Zane	NULL
7	NULL
)	NULL
plus	NULL
rabbit	NULL
anti-mouse	NULL
(	NULL
Zane	NULL
8	NULL
)	NULL
or	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Differential	NULL
Signaling	NULL
through	NULL
CD28	NULL
by	NULL
Ligands	NULL
CD80	NULL
and	NULL
CD86	NULL
3121	NULL
5	NULL
5	NULL
C	NULL
ae	NULL
x	NULL
C	NULL
4	NULL
€	NULL
)	NULL
5	NULL
3	NULL
€	NULL
S	NULL
S	NULL
E	NULL
&	NULL
R	NULL
6	NULL
&	NULL
5	NULL
_	NULL
cHo-cpso	NULL
_	NULL
?	NULL

2	NULL
_	NULL
_cho-cose	NULL
_	NULL
©	NULL
Z	NULL
O	NULL
O	NULL
pr	NULL
30s	NULL
2m	NULL
5m	NULL
10m	NULL
30s	NULL
2m	NULL
Sm	NULL
10m	NULL
«	NULL
ue	NULL
.	NULL

quits	NULL
.	NULL

cms	NULL
‘	NULL
swe	NULL
.	NULL

smae	NULL
+	NULL
V	NULL
a	NULL
V	NULL
is	NULL
P	NULL
am	NULL
ams	NULL
ams	NULL
cus	NULL
aun	NULL
cass	NULL
ath	NULL
Tih	NULL
Gis	NULL
«	NULL
a	NULL
»	NULL
Tih	NULL
Gh	NULL
4-	NULL
\/	NULL
a\	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Both	NULL
CHO-CD80	NULL
and	NULL
CHO-CD86	NULL
induce	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
VAV	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Anti-VAV	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
not	NULL
treated	NULL
,	NULL
stimulated	NULL
with	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
or	NULL
CHO-CD86	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
and	NULL
then	NULL
warmed	NULL
to	NULL
87	NULL
°C	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

Stimulations	NULL
were	NULL
stopped	NULL
and	NULL
cells	NULL
lysed	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

Lysates	NULL
were	NULL
clarified	NULL
by	NULL
centrifugation	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-VAV	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Lysates	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
PVDF	NULL
,	NULL
and	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
detected	NULL
by	NULL
ECL	NULL
(	NULL
fop	NULL
)	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
anti-VAV	NULL
antibody	NULL
to	NULL
demonstrate	NULL
equivalent	NULL
loading	NULL
of	NULL
proteins	NULL
(	NULL
bottom	NULL
)	NULL
.	NULL

+	NULL
Jurkat	NULL
CHO-CD80	NULL
CHO-Mock	NULL
CHO-CD80	NULL
CHO-CD86	NULL
«	NULL
CD3	NULL
mAb	NULL
a	NULL
CD28	NULL
mAb	NULL
0	NULL
phospho	NULL
c-cbl	NULL
-*	NULL
-	NULL
97	NULL
o	NULL
c-cbl	NULL
-	NULL
|__	NULL
~-	NULL
eaid	NULL
an	NULL
dban	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
of	NULL
CBL	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
anti-CD3	NULL
mAb	NULL
,	NULL
CHO-CD80	NULL
,	NULL
and	NULL
CHO-CD86	NULL
.	NULL

Anti-CBL	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
CHO-CD80	NULL
cells	NULL
alone	NULL
or	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
left	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
or	NULL
CHO-CD86	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
,	NULL
6	NULL
pg/ml	NULL
anti-CD3	NULL
mAb	NULL
,	NULL
or	NULL
4	NULL
ug/ml	NULL
anti-CD28	NULL
mAb	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
and	NULL
then	NULL
5	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Stimulations	NULL
were	NULL
stopped	NULL
and	NULL
cells	NULL
lysed	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

Lysates	NULL
were	NULL
clarified	NULL
by	NULL
centrifugation	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-CBL	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Lysates	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
through	NULL
SDS-PAGE	NULL
and	NULL
then	NULL
transferred	NULL
to	NULL
PVDF	NULL
membranes	NULL
.	NULL

Tyrosine-phosphorylated	NULL
proteins	NULL
were	NULL
detected	NULL
with	NULL
anti-phosphotyrosine	NULL
antibody	NULL
(	NULL
RC20	NULL
1:2500	NULL
dilution	NULL
)	NULL
for	NULL
2	NULL
h	NULL
,	NULL
and	NULL
the	NULL
proteins	NULL
were	NULL
visualized	NULL
by	NULL
ECL	NULL
(	NULL
top	NULL
)	NULL
.	NULL

The	NULL
migration	NULL
of	NULL
molecular	NULL
mass	NULL
markers	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
anti-CBL	NULL
to	NULL
verify	NULL
equivalent	NULL
protein	NULL
levels	NULL
(	NULL
bottom	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
as	NULL
predicted	NULL
by	NULL
the	NULL
in	NULL
vivo	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
,	NULL
there	NULL
was	NULL
much	NULL
less	NULL
PI3-K	NULL
associated	NULL
with	NULL
CD28	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
CD4*	NULL
human	NULL
peripheral	NULL
T	NULL
cells	NULL
after	NULL
CD86	NULL
stimulation	NULL
compared	NULL
with	NULL
CD80	NULL
stimulation	NULL
.	NULL

Peptide	NULL
competition	NULL
studies	NULL
were	NULL
performed	NULL
to	NULL
ensure	NULL
that	NULL
the	NULL
CD86-dependent	NULL
CD28-PI3-K	NULL
complex	NULL
formed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
detectable	NULL
levels	NULL
of	NULL
CD28	NULL
tyrosine	NULL
phosphorylation	NULL
remained	NULL
SH2-dependent	NULL
.	NULL

Incubation	NULL
of	NULL
CD28	NULL
immunoprecipitates	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cell	NULL
lysates	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
or	NULL
CD4*	NULL
human	NULL
peripheral	NULL
blood	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8D	NULL
)	NULL
with	NULL
the	NULL
-Tyr	NULL
(	NULL
P	NULL
)	NULL
-Met-Asn-Met-containing	NULL
peptide	NULL
,	NULL
but	NULL
not	NULL
with	NULL
its	NULL
unphosphorylated	NULL
-Tyr-Met-Asn-Met-	NULL
counterpart	NULL
,	NULL
inhibited	NULL
the	NULL
association	NULL
of	NULL
PI3-K	NULL
with	NULL
CD28	NULL
after	NULL
ligation	NULL
with	NULL
either	NULL
CD80	NULL
and	NULL
CD86	NULL
.	NULL

Thus	NULL
,	NULL
CD86	NULL
induced	NULL
minimal	NULL
increases	NULL
in	NULL
the	NULL
in	NULL
vivo	NULL
phosphorylation	NULL
of	NULL
Tyr	NULL
'	NULL
``	NULL
``	NULL
below	NULL
the	NULL
limits	NULL
of	NULL
detection	NULL
using	NULL
the	NULL
deglycosylation	NULL
procedure	NULL
described	NULL
above	NULL
.	NULL

The	NULL
minimal	NULL
CD28	NULL
phosphorylation	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
relatively	NULL
poor	NULL
ability	NULL
of	NULL
CD86	NULL
to	NULL
induce	NULL
the	NULL
binding	NULL
of	NULL
PI3-K	NULL
to	NULL
CD28	NULL
when	NULL
compared	NULL
directly	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
or	NULL
CD80	NULL
stimulation	NULL
.	NULL

A	NULL
+	NULL
Jurkat	NULL
£	NULL
o	NULL
<	NULL
§	NULL
a	NULL
4	NULL
o	NULL
x	NULL
7.54	NULL
8	NULL
§	NULL
§	NULL
4	NULL
:	NULL
fl	NULL
9	NULL
2	NULL
9	NULL
0	NULL
E	NULL
a	NULL
8	NULL
©	NULL
o	NULL
o	NULL
2	NULL
9	NULL
292	NULL
2	NULL
06	NULL
0	NULL
0	NULL
0	NULL
G	NULL
0	NULL
2	NULL
s	NULL
s	NULL
217-wee	NULL
ams	NULL
c	NULL
>	NULL
CW	NULL
<	NULL
-	NULL
|	NULL
<	NULL
-PLC-41	NULL
J	NULL
+	NULL
8	NULL
,	NULL
o	NULL
CHO-CD80	NULL
CHO-Mock	NULL
CHO-CD80	NULL
CHO-CDS86	NULL
«	NULL
am	NULL
<	NULL
-PLC-y1	NULL
I	NULL
FiG	NULL
.	NULL

6	NULL
.	NULL

Phospholipase	NULL
Cyl	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
induced	NULL
by	NULL
CHO-CD80	NULL
but	NULL
not	NULL
by	NULL
CHO-CD86	NULL
.	NULL

A	NULL
,	NULL
anti-phosphotyrosine	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
CHO-CD80	NULL
cells	NULL
alone	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
or	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
left	NULL
untreated	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
,	NULL
or	NULL
treated	NULL
with	NULL
CHO-Mock	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
,	NULL
CHO-CD80	NULL
(	NULL
Zane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
CHO-CD86	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
,	NULL
4	NULL
ug/ml	NULL
anti-CD28	NULL
mAb	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
or	NULL
6	NULL
ug/ml	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
Zane	NULL
6	NULL
)	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
followed	NULL
by	NULL
5	NULL
min	NULL
at	NULL
87	NULL
°C	NULL
.	NULL

Sample	NULL
were	NULL
processed	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

34	NULL
.	NULL

Proteins	NULL
were	NULL
visualized	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-PLCy1	NULL
antibody	NULL
.	NULL

The	NULL
migrations	NULL
of	NULL
molecular	NULL
mass	NULL
markers	NULL
are	NULL
indicated	NULL
.	NULL

B	NULL
,	NULL
anti-phosphotyrosine	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
,	NULL
processed	NULL
,	NULL
and	NULL
proteins	NULL
visualized	NULL
as	NULL
in	NULL
A	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
CHO-CD80	NULL
alone	NULL
or	NULL
from	NULL
CD4®	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
treated	NULL
with	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
or	NULL
CHO-CD86	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
found	NULL
quantitative	NULL
differences	NULL
between	NULL
the	NULL
CD28-dependent	NULL
signaling	NULL
responses	NULL
elicited	NULL
by	NULL
the	NULL
two	NULL
B7	NULL
family	NULL
members	NULL
,	NULL
CD80	NULL
and	NULL
CD86	NULL
.	NULL

In	NULL
our	NULL
studies	NULL
,	NULL
CD80	NULL
and	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
but	NULL
not	NULL
CD86	NULL
,	NULL
induced	NULL
the	NULL
robust	NULL
and	NULL
sustained	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
itself	NULL
.	NULL

CD86	NULL
stimulation	NULL
was	NULL
unable	NULL
to	NULL
induce	NULL
detectable	NULL
in	NULL
vivo	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
at	NULL
any	NULL
time	NULL
point	NULL
examined	NULL
.	NULL

This	NULL
dramatic	NULL
difference	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
to	NULL
stimulate	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
was	NULL
reflected	NULL
in	NULL
the	NULL
differential	NULL
ability	NULL
of	NULL
the	NULL
two	NULL
ligands	NULL
to	NULL
stimulate	NULL
the	NULL
SH2-dependent	NULL
association	NULL
of	NULL
PI3-K	NULL
with	NULL
CD28	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
3122	NULL
g	NULL
{	NULL
$	NULL
&	NULL
%	NULL
a	NULL
8§855	NULL
$	NULL
98§a	NULL
o	NULL
0	NULL
©	NULL
Q	NULL
I	NULL
E	NULL
E	NULL
eo	NULL
C	NULL
0	NULL
8	NULL
06	NULL
2	NULL
:	NULL
CD28	NULL
-	NULL
»	NULL
«	NULL
tliis	NULL
P	NULL
Minutes	NULL
__	NULL
0	NULL
1	NULL
5	NULL
15	NULL
30	NULL
o	NULL
©	NULL
o	NULL
©	NULL
o	NULL
©	NULL
o	NULL
©	NULL
o	NULL
©	NULL
®	NULL
a	NULL
©	NULL
a	NULL
o	NULL
®	NULL
o	NULL
®	NULL
®	NULL
®	NULL
o	NULL
A	NULL
A	NULL
a	NULL
a	NULL
A	NULL
A	NULL
A	NULL
aA	NULL
A	NULL
9	NULL
9	NULL
Q9	NULL
Q	NULL
Q	NULL
Q	NULL
Q	NULL
Q	NULL
Q	NULL
Q	NULL
0	NULL
6	NULL
06	NULL
6	NULL
o	NULL
o	NULL
o	NULL
o	NULL
6	NULL
0	NULL
L	NULL
&	NULL
£	NULL
%	NULL
Z	NULL
Z	NULL
I	NULL
ZL	NULL
LI	NULL
I	NULL
5	NULL
G	NULL
5	NULL
G6	NULL
5	NULL
5	NULL
5	NULL
5	NULL
5	NULL
5	NULL
CD28	NULL
-	NULL
»	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

CHO-CD80	NULL
but	NULL
not	NULL
CHO-CD86	NULL
induces	NULL
the	NULL
robust	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
.	NULL

A	NULL
,	NULL
anti-CD28	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
2.5	NULL
X	NULL
10	NULL
``	NULL
Jurkat	NULL
cells	NULL
left	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
CHO-CD86	NULL
cells	NULL
(	NULL
1.25	NULL
X	NULL
10	NULL
``	NULL
)	NULL
or	NULL
with	NULL
4	NULL
pg/ml	NULL
anti-CD28	NULL
mAb	NULL
.	NULL

Stimulations	NULL
were	NULL
stopped	NULL
and	NULL
cells	NULL
lysed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
2X	NULL
detergent	NULL
lysis	NULL
buffer	NULL
.	NULL

Anti-CD28	NULL
mAb	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
were	NULL
added	NULL
to	NULL
all	NULL
samples	NULL
post-lysis	NULL
,	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
incubated	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
2	NULL
h.	NULL
The	NULL
samples	NULL
were	NULL
washed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
1000	NULL
units	NULL
peptide	NULL
:	NULL
N-glycosidase	NULL
F	NULL
for	NULL
1	NULL
h	NULL
before	NULL
separation	NULL
on	NULL
SDS-PAGE	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
transferred	NULL
to	NULL
PVDF	NULL
,	NULL
blotted	NULL
with	NULL
anti-phosphotyrosine	NULL
antibody	NULL
,	NULL
and	NULL
detected	NULL
by	NULL
ECL	NULL
.	NULL

B	NULL
,	NULL
anti-CD28	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
and	NULL
processed	NULL
as	NULL
in	NULL
A	NULL
from	NULL
2.5	NULL
X	NULL
10	NULL
``	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
1.25	NULL
x	NULL
10	NULL
``	NULL
CHO-CD80	NULL
or	NULL
with	NULL
1.25	NULL
x	NULL
10	NULL
``	NULL
CHO-CD86	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

The	NULL
data	NULL
reported	NULL
here	NULL
and	NULL
other	NULL
studies	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
both	NULL
CD80	NULL
and	NULL
CD86	NULL
are	NULL
able	NULL
to	NULL
induce	NULL
the	NULL
association	NULL
of	NULL
PI3-K	NULL
with	NULL
CD28	NULL
and	NULL
that	NULL
this	NULL
association	NULL
is	NULL
dependent	NULL
upon	NULL
the	NULL
phosphorylated	NULL
YMNM	NULL
motif	NULL
of	NULL
the	NULL
CD28	NULL
cytoplasmic	NULL
do-main	NULL
.	NULL

Our	NULL
conclusions	NULL
differ	NULL
,	NULL
however	NULL
,	NULL
from	NULL
those	NULL
of	NULL
Rudd	NULL
and	NULL
colleagues	NULL
(	NULL
22	NULL
)	NULL
who	NULL
reported	NULL
no	NULL
difference	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
to	NULL
induce	NULL
the	NULL
SH2-dependent	NULL
association	NULL
of	NULL
PI3-K	NULL
and	NULL
CD28	NULL
.	NULL

These	NULL
investigators	NULL
studied	NULL
a	NULL
murine	NULL
CD28	NULL
*	NULL
hybridoma	NULL
transfected	NULL
with	NULL
human	NULL
CD28	NULL
that	NULL
was	NULL
stimulated	NULL
with	NULL
plate-bound	NULL
CHO	NULL
cells	NULL
expressing	NULL
murine	NULL
CD80	NULL
and	NULL
CD86	NULL
proteins	NULL
;	NULL
both	NULL
CD80	NULL
and	NULL
CD86	NULL
induced	NULL
the	NULL
association	NULL
of	NULL
PI3-K	NULL
with	NULL
CD28	NULL
.	NULL

It	NULL
remains	NULL
possible	NULL
that	NULL
endogenous	NULL
murine	NULL
CD28	NULL
with	NULL
the	NULL
murine	NULL
ligands	NULL
contributed	NULL
to	NULL
the	NULL
responses	NULL
observed	NULL
in	NULL
their	NULL
system	NULL
or	NULL
,	NULL
more	NULL
likely	NULL
,	NULL
that	NULL
the	NULL
interspecies	NULL
interaction	NULL
may	NULL
have	NULL
masked	NULL
the	NULL
intraspecies	NULL
specificity	NULL
,	NULL
i.e	NULL
.	NULL

that	NULL
the	NULL
interaction	NULL
of	NULL
human	NULL
CD28	NULL
with	NULL
the	NULL
murine	NULL
ligands	NULL
did	NULL
not	NULL
faithfully	NULL
reflect	NULL
species-specific	NULL
signaling	NULL
events	NULL
.	NULL

Al-ternatively	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
quantitative	NULL
differences	NULL
observed	NULL
may	NULL
relate	NULL
to	NULL
differences	NULL
between	NULL
our	NULL
specific	NULL
experimental	NULL
culture	NULL
conditions	NULL
.	NULL

Using	NULL
purified	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
Olive	NULL
and	NULL
colleagues	NULL
(	NULL
39	NULL
)	NULL
also	NULL
demonstrated	NULL
that	NULL
both	NULL
CD80	NULL
and	NULL
CD86	NULL
induced	NULL
the	NULL
SH2-dependent	NULL
association	NULL
of	NULL
CD28	NULL
with	NULL
PI3-K	NULL
.	NULL

However	NULL
,	NULL
they	NULL
further	NULL
demonstrated	NULL
that	NULL
wortmannin	NULL
,	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
lipid	NULL
kinase	NULL
activity	NULL
of	NULL
PI3-K	NULL
via	NULL
binding	NULL
to	NULL
the	NULL
p110	NULL
subunit	NULL
,	NULL
inhibited	NULL
CD80	NULL
costimulation	NULL
of	NULL
IL-2	NULL
production	NULL
more	NULL
efficiently	NULL
than	NULL
CD86	NULL
costimulation	NULL
(	NULL
IC	NULL
;	NULL
,	NULL
25	NULL
and	NULL
110	NULL
nM	NULL
,	NULL
respec-tively	NULL
)	NULL
(	NULL
39	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
the	NULL
dependence	NULL
on	NULL
PI3	NULL
lipid	NULL
kinase	NULL
activity	NULL
of	NULL
CD80	NULL
and	NULL
CD86	NULL
stimulation	NULL
differed	NULL
,	NULL
an	NULL
observation	NULL
consistent	NULL
with	NULL
our	NULL
results	NULL
.	NULL

PI3-K	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
upstream	NULL
of	NULL
Akt/PKB	NULL
in	NULL
other	NULL
systems	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
as	NULL
well	NULL
as	NULL
upstream	NULL
of	NULL
p7O	NULL
S6	NULL
kinase	NULL
(	NULL
42	NULL
,	NULL
43	NULL
)	NULL
,	NULL
both	NULL
of	NULL
which	NULL
may	NULL
impact	NULL
on	NULL
cell	NULL
survival	NULL
and	NULL
proliferation	NULL
and	NULL
therefore	NULL
on	NULL
the	NULL
functional	NULL
outcome	NULL
of	NULL
CD80	NULL
versus	NULL
CD86	NULL
stimulation	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
CD80	NULL
,	NULL
CD86	NULL
failed	NULL
to	NULL
induce	NULL
the	NULL
detectable	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
.	NULL

We	NULL
appreciate	NULL
that	NULL
PI3-K	NULL
Differential	NULL
Signaling	NULL
through	NULL
CD28	NULL
by	NULL
Ligands	NULL
CD80	NULL
and	NULL
CD86	NULL
binding	NULL
to	NULL
the	NULL
CD28	NULL
receptor	NULL
is	NULL
a	NULL
more	NULL
sensitive	NULL
assay	NULL
for	NULL
CD28	NULL
tyrosyl	NULL
phosphorylation	NULL
than	NULL
immunoblotting	NULL
of	NULL
precip-itated	NULL
,	NULL
deglycosylated	NULL
CD28	NULL
polypeptide	NULL
.	NULL

Nevertheless	NULL
,	NULL
dramatic	NULL
quantitative	NULL
differences	NULL
between	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
two	NULL
ligands	NULL
to	NULL
induce	NULL
CD28	NULL
tyrosine	NULL
phosphorylation	NULL
were	NULL
ob-served	NULL
,	NULL
and	NULL
a	NULL
number	NULL
of	NULL
potential	NULL
mechanisms	NULL
to	NULL
explain	NULL
this	NULL
observation	NULL
should	NULL
be	NULL
entertained	NULL
.	NULL

The	NULL
more	NULL
rapid	NULL
dissociation	NULL
of	NULL
CD86	NULL
from	NULL
CD28	NULL
(	NULL
5	NULL
)	NULL
may	NULL
not	NULL
permit	NULL
the	NULL
robust	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
that	NULL
the	NULL
relatively	NULL
more	NULL
prolonged	NULL
binding	NULL
of	NULL
CD80	NULL
induced	NULL
.	NULL

Simply	NULL
increasing	NULL
the	NULL
expression	NULL
of	NULL
CD86	NULL
did	NULL
not	NULL
overcome	NULL
or	NULL
compensate	NULL
for	NULL
the	NULL
observed	NULL
difference	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Not	NULL
only	NULL
do	NULL
kinetic	NULL
differences	NULL
in	NULL
the	NULL
association/dissociation	NULL
of	NULL
CD80/CD28	NULL
and	NULL
CD86/CD28	NULL
exist	NULL
but	NULL
structural	NULL
differences	NULL
in	NULL
these	NULL
interactions	NULL
have	NULL
been	NULL
documented	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
LDN	NULL
residues	NULL
of	NULL
the	NULL
M°°YPPPYLDN*	NULL
``	NULL
region	NULL
of	NULL
CD28	NULL
reduced	NULL
both	NULL
CD80	NULL
and	NULL
CD86	NULL
binding	NULL
(	NULL
6	NULL
)	NULL
,	NULL
whereas	NULL
mutation	NULL
of	NULL
Tyr	NULL
'	NULL
``	NULL
°	NULL
and	NULL
Tyr	NULL
'	NULL
``	NULL
*	NULL
selectively	NULL
reduced	NULL
CD86	NULL
binding	NULL
without	NULL
impacting	NULL
upon	NULL
CD80	NULL
binding	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
discrepancy	NULL
in	NULL
the	NULL
conformation	NULL
of	NULL
CD28	NULL
upon	NULL
CD80	NULL
binding	NULL
from	NULL
that	NULL
resulting	NULL
from	NULL
the	NULL
CD86	NULL
binding	NULL
may	NULL
have	NULL
resulted	NULL
in	NULL
divergent	NULL
downstream	NULL
signaling	NULL
cascades	NULL
.	NULL

Finally	NULL
,	NULL
CD86	NULL
may	NULL
selectively	NULL
and	NULL
rapidly	NULL
recruit	NULL
and/or	NULL
activate	NULL
a	NULL
tyrosine	NULL
phosphatase	NULL
that	NULL
dephosphorylated	NULL
the	NULL
-Tyr	NULL
(	NULL
P	NULL
)	NULL
-Met-Asn-Met-	NULL
motif	NULL
of	NULL
the	NULL
CD28	NULL
cytoplasmic	NULL
tail	NULL
,	NULL
thereby	NULL
resulting	NULL
in	NULL
lower	NULL
levels	NULL
of	NULL
CD28	NULL
phosphorylation	NULL
and	NULL
diminished	NULL
PI3-K	NULL
binding	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
,	NULL
however	NULL
,	NULL
that	NULL
despite	NULL
the	NULL
absence	NULL
of	NULL
detectable	NULL
CD28	NULL
phosphorylation	NULL
,	NULL
CD86	NULL
costimulated	NULL
cytokine	NULL
production	NULL
and	NULL
NFAT	NULL
mediated	NULL
transcriptional	NULL
activation	NULL
.	NULL

The	NULL
NFAT-mediated	NULL
transcriptional	NULL
activation	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
blocking	NULL
CD28	NULL
mAb	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
confirming	NULL
that	NULL
CD86	NULL
was	NULL
signaling	NULL
through	NULL
CD28	NULL
.	NULL

It	NULL
remains	NULL
possible	NULL
that	NULL
the	NULL
mechanism	NULL
of	NULL
CD86-dependent	NULL
cytokine	NULL
production	NULL
and	NULL
transcriptional	NULL
activation	NULL
may	NULL
differ	NULL
from	NULL
CD80-dependent	NULL
activation	NULL
of	NULL
the	NULL
same	NULL
events	NULL
.	NULL

CD86	NULL
stimulation	NULL
may	NULL
recruit	NULL
another	NULL
protein	NULL
(	NULL
cytoplasmic	NULL
or	NULL
transmembrane	NULL
)	NULL
to	NULL
CD28	NULL
,	NULL
resulting	NULL
in	NULL
activation	NULL
of	NULL
a	NULL
slightly	NULL
different	NULL
cascade	NULL
of	NULL
signaling	NULL
events	NULL
that	NULL
nonetheless	NULL
culminate	NULL
in	NULL
cytokine	NULL
gene	NULL
transcription	NULL
.	NULL

Regardless	NULL
,	NULL
either	NULL
the	NULL
minimal	NULL
level	NULL
of	NULL
CD28	NULL
phosphorylation	NULL
achieved	NULL
by	NULL
CD86/CD28	NULL
interactions	NULL
is	NULL
sufficient	NULL
for	NULL
cytokine	NULL
production	NULL
or	NULL
CD28	NULL
phosphorylation	NULL
is	NULL
itself	NULL
not	NULL
required	NULL
for	NULL
cytokine	NULL
production	NULL
.	NULL

There	NULL
are	NULL
precedents	NULL
for	NULL
two	NULL
different	NULL
ligands	NULL
of	NULL
a	NULL
single	NULL
receptor	NULL
to	NULL
signal	NULL
differently	NULL
through	NULL
that	NULL
receptor	NULL
even	NULL
when	NULL
contacting	NULL
amino	NULL
acids	NULL
overlap	NULL
.	NULL

A	NULL
compelling	NULL
example	NULL
is	NULL
T	NULL
cell	NULL
receptor	NULL
stimulation	NULL
by	NULL
native	NULL
versus	NULL
altered	NULL
peptide	NULL
ligand	NULL
;	NULL
here	NULL
,	NULL
peptides	NULL
that	NULL
differ	NULL
at	NULL
specific	NULL
amino	NULL
acid	NULL
residues	NULL
interact	NULL
with	NULL
a	NULL
clonogenic	NULL
TcR	NULL
to	NULL
modify	NULL
early	NULL
intracellular	NULL
signaling	NULL
events	NULL
(	NULL
e.g	NULL
.	NULL

phosphorylation	NULL
of	NULL
Zap-70	NULL
and	NULL
calcium	NULL
mobili-zation	NULL
)	NULL
(	NULL
44	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
nonmitogenic	NULL
antibodies	NULL
to	NULL
CD3	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
result	NULL
in	NULL
ineffective	NULL
TeR	NULL
{	NULL
and	NULL
Zap-70	NULL
phosphorylation	NULL
,	NULL
minimal	NULL
PLC-y1	NULL
phosphorylation	NULL
,	NULL
and	NULL
diminished	NULL
calcium	NULL
mobilization	NULL
(	NULL
45	NULL
)	NULL
,	NULL
compared	NULL
with	NULL
mitogenic	NULL
antibodies	NULL
binding	NULL
to	NULL
different	NULL
sites	NULL
on	NULL
the	NULL
same	NULL
CD3	NULL
molecule	NULL
.	NULL

Although	NULL
the	NULL
TcR	NULL
is	NULL
a	NULL
multichain	NULL
complex	NULL
and	NULL
CD28	NULL
exists	NULL
as	NULL
a	NULL
ho-modimer	NULL
,	NULL
oligomerization	NULL
of	NULL
CD28	NULL
may	NULL
be	NULL
one	NULL
mechanism	NULL
permitting	NULL
analogous	NULL
regulation	NULL
of	NULL
CD28	NULL
signaling	NULL
pathways	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
a	NULL
completely	NULL
different	NULL
system	NULL
,	NULL
estrogen	NULL
receptor	NULL
binding	NULL
by	NULL
two	NULL
different	NULL
estrogenic	NULL
entities	NULL
(	NULL
estrogen	NULL
and	NULL
raloxifene	NULL
)	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
regulate	NULL
two	NULL
different	NULL
DNA	NULL
response	NULL
elements	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
biochemical	NULL
differences	NULL
following	NULL
CD80-	NULL
and	NULL
CD86-dependent	NULL
signaling	NULL
we	NULL
report	NULL
here	NULL
might	NULL
have	NULL
been	NULL
predicted	NULL
by	NULL
earlier	NULL
work	NULL
(	NULL
47	NULL
)	NULL
demonstrating	NULL
that	NULL
stimulation	NULL
with	NULL
different	NULL
anti-CD28	NULL
mAbs	NULL
had	NULL
different	NULL
outcomes	NULL
with	NULL
regard	NULL
to	NULL
calcium	NULL
flux	NULL
and	NULL
IL-2	NULL
production	NULL
.	NULL

To	NULL
a	NULL
first	NULL
approximation	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
PLC-y1	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
generate	NULL
diacylglycerol	NULL
and	NULL
inositol	NULL
triphosphates	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Differential	NULL
Signaling	NULL
through	NULL
CD28	NULL
by	NULL
Ligands	NULL
CD80	NULL
and	NULL
CD86	NULL
3123	NULL
A	NULL
B	NULL
5	NULL
5	NULL
5	NULL
o	NULL
o	NULL
8	NULL
2	NULL
xo	NULL
s	NULL
s	NULL
§	NULL
2	NULL
x~	NULL
o	NULL
&	NULL
€	NULL
€	NULL
8	NULL
§	NULL
G	NULL
f	NULL
§	NULL
§	NULL
§	NULL
S	NULL
t	NULL
t	NULL
§	NULL
§	NULL
G	NULL
f	NULL
=	NULL
o	NULL
0	NULL
E	NULL
g	NULL
=	NULL
Q	NULL
9	NULL
Eg	NULL
z	NULL
9	NULL
9	NULL
E	NULL
g	NULL
2	NULL
2	NULL
2	NULL
2	NULL
8	NULL
2	NULL
9	NULL
R	NULL
T	NULL
f	NULL
&	NULL
&	NULL
£	NULL
?	NULL

8	NULL
0	NULL
o	NULL
o	NULL
000295	NULL
0	NULL
Oo	NULL
O	NULL
2	NULL
s	NULL
O	NULL
O	NULL
O	NULL
Z2	NULL
8	NULL
rex	NULL
(	NULL
__	NULL
cas	NULL
nes	NULL
+	NULL
YMNM	NULL
+	NULL
P-YMNM	NULL
C	NULL
§	NULL
.	NULL

P	NULL
s	NULL
5	NULL
3	NULL
o	NULL
o	NULL
3	NULL
<	NULL
x	NULL
o	NULL
o	NULL
a	NULL
2	NULL
o	NULL
£	NULL
&	NULL
~	NULL
g	NULL
o	NULL
4	NULL
2	NULL
,	NULL
§	NULL
§	NULL
&	NULL
f	NULL
:	NULL
§	NULL
B§	NULL
|	NULL
=	NULL
9	NULL
9	NULL
E	NULL
g	NULL
=	NULL
9	NULL
0	NULL
Eqz	NULL
9	NULL
0m	NULL
Ez	NULL
0	NULL
0	NULL
Eg	NULL
§	NULL
2	NULL
5	NULL
£	NULL
i	NULL
8	NULL
9	NULL
go	NULL
fag	NULL
g	NULL
9d	NULL
29	NULL
gg	NULL
°o	NULL
c	NULL
6	NULL
56	NULL
o	NULL
2	NULL
§	NULL
o	NULL
s	NULL
5	NULL
2	NULL
85	NULL
s	NULL
5	NULL
%	NULL
$	NULL
56	NULL
s	NULL
5	NULL
2	NULL
%	NULL
:	NULL
«	NULL
[	NULL
_-	NULL
____-	NULL
_-	NULL
@	NULL
-	NULL
»	NULL
+YMNM	NULL
+	NULL
P-YMNM	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

PIS-K	NULL
associates	NULL
in	NULL
an	NULL
SH2-dependent	NULL
fashion	NULL
with	NULL
CD28	NULL
after	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
CHO-CD80	NULL
,	NULL
and	NULL
CHO-CD86	NULL
.	NULL

A	NULL
,	NULL
anti-CD28	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
1	NULL
X	NULL
10	NULL
``	NULL
Jurkat	NULL
cells	NULL
treated	NULL
as	NULL
indicated	NULL
with	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
CHO-CD86	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
or	NULL
4	NULL
ug/ml	NULL
mAb	NULL
9.3	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
and	NULL
then	NULL
warmed	NULL
to	NULL
37	NULL
°C	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Stimulations	NULL
were	NULL
stopped	NULL
and	NULL
cells	NULL
lysed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
2X	NULL
detergent	NULL
lysis	NULL
buffer	NULL
.	NULL

Anti-CD28	NULL
mAb	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
were	NULL
added	NULL
to	NULL
all	NULL
samples	NULL
post-lysis	NULL
,	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
incubated	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
2	NULL
h.	NULL
Immunoprecipitates	NULL
were	NULL
washed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
,	NULL
``	NULL
and	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
through	NULL
a	NULL
6-15	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
transferred	NULL
to	NULL
PVDF	NULL
.	NULL

Membranes	NULL
were	NULL
incubated	NULL
with	NULL
antibody	NULL
to	NULL
the	NULL
p85	NULL
subunit	NULL
of	NULL
PIS-K	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
washed	NULL
,	NULL
incubated	NULL
with	NULL
secondary	NULL
antibody	NULL
coupled	NULL
to	NULL
horseradish	NULL
peroxidase	NULL
,	NULL
and	NULL
proteins	NULL
were	NULL
visualized	NULL
by	NULL
ECL	NULL
.	NULL

B	NULL
,	NULL
jurkat	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
as	NULL
described	NULL
in	NULL
A	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
anti-CD28	NULL
mAb	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
,	NULL
5	NULL
uM	NULL
-Tyr-Met-Asn-Met-	NULL
or	NULL
-Tyr	NULL
(	NULL
P	NULL
)	NULL
-Met-Asn-Met-containing	NULL
peptide	NULL
was	NULL
added	NULL
to	NULL
samples	NULL
post-lysis	NULL
.	NULL

C	NULL
,	NULL
anti-CD28	NULL
immunoprecipitates	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
in	NULL
A	NULL
from	NULL
2	NULL
X	NULL
10	NULL
``	NULL
CD4*	NULL
T	NULL
cells	NULL
left	NULL
unstimulated	NULL
,	NULL
stimulated	NULL
with	NULL
CHO-Mock	NULL
,	NULL
-CD80	NULL
,	NULL
-CD86	NULL
CHO	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
or	NULL
with	NULL
4	NULL
ug/ml	NULL
anti-CD28	NULL
mAb	NULL
or	NULL
15	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
,	NULL
and	NULL
then	NULL
warmed	NULL
to	NULL
37	NULL
°C	NULL
for	NULL
15	NULL
min	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
treated	NULL
exactly	NULL
as	NULL
in	NULL
A	NULL
.	NULL

D	NULL
,	NULL
CD4*	NULL
human	NULL
peripheral	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
CHO-Mock	NULL
,	NULL
CHO-CD80	NULL
,	NULL
or	NULL
CHO-CD86	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
to	NULL
anti-CD28	NULL
mAb	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
,	NULL
5	NULL
uM	NULL
-Tyr-Met-Asn-Met-	NULL
or	NULL
-Tyr	NULL
(	NULL
P	NULL
)	NULL
-Met-Asn-Met-containing	NULL
peptide	NULL
was	NULL
added	NULL
to	NULL
samples	NULL
post-lysis	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
washed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
and	NULL
treated	NULL
as	NULL
in	NULL
A.	NULL
that	NULL
in	NULL
turn	NULL
result	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
the	NULL
-	NULL
able	NULL
to	NULL
induce	NULL
the	NULL
phosphorylation	NULL
of	NULL
CBL	NULL
,	NULL
a	NULL
protein	NULL
able	NULL
to	NULL
release	NULL
of	NULL
calcium	NULL
from	NULL
intracellular	NULL
stores	NULL
,	NULL
respectively	NULL
.	NULL

CD80	NULL
-	NULL
bind	NULL
constitutively	NULL
with	NULL
PI3-K	NULL
and	NULL
,	NULL
upon	NULL
activation	NULL
,	NULL
with	NULL
stimulates	NULL
the	NULL
rapid	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLC-y1	NULL
;	NULL
there	NULL
-	NULL
p59	NULL
``	NULL
``	NULL
``	NULL
(	NULL
51-53	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
phosphorylation	NULL
of	NULL
both	NULL
VAV	NULL
and	NULL
is	NULL
no	NULL
discernible	NULL
phosphorylation	NULL
following	NULL
stimulation	NULL
with	NULL
-	NULL
CBL	NULL
after	NULL
stimulation	NULL
with	NULL
either	NULL
CD80	NULL
or	NULL
CD86	NULL
may	NULL
be	NULL
to	NULL
CD86	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
CD80	NULL
to	NULL
induce	NULL
the	NULL
tyrosine	NULL
-	NULL
provide	NULL
a	NULL
means	NULL
to	NULL
assemble	NULL
a	NULL
macromolecular	NULL
signaling	NULL
com-phosphorylation	NULL
of	NULL
PLC-y1	NULL
correlated	NULL
with	NULL
its	NULL
ability	NULL
to	NULL
induce	NULL
-	NULL
plex	NULL
,	NULL
common	NULL
features	NULL
of	NULL
which	NULL
may	NULL
initiate	NULL
signaling	NULL
trans-the	NULL
in	NULL
vivo	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
itself	NULL
and	NULL
the	NULL
-	NULL
mission	NULL
cascades	NULL
leading	NULL
to	NULL
their	NULL
shared	NULL
functional	NULL
properties	NULL
.	NULL

enhanced	NULL
association	NULL
of	NULL
PIS-K	NULL
with	NULL
CD28	NULL
.	NULL

Buhl	NULL
et	NULL
al	NULL
.	NULL

(	NULL
48	NULL
)	NULL
We	NULL
have	NULL
shown	NULL
differing	NULL
biochemical	NULL
outcomes	NULL
between	NULL
recently	NULL
demonstrated	NULL
that	NULL
the	NULL
absence	NULL
of	NULL
CD19	NULL
resulted	NULL
in	NULL
-	NULL
CD80	NULL
and	NULL
CD86	NULL
ligation	NULL
;	NULL
although	NULL
these	NULL
differences	NULL
appear	NULL
to	NULL
decreased	NULL
antigen-induced	NULL
PI3-K	NULL
activity	NULL
,	NULL
as	NULL
well	NULL
as	NULL
decreased	NULL
-	NULL
be	NULL
quantitative	NULL
and	NULL
not	NULL
absolute	NULL
,	NULL
quantitative	NULL
signaling	NULL
differ-phosphoinositide	NULL
hydrolysis	NULL
and	NULL
calcium	NULL
mobilization	NULL
.	NULL

Fur-	NULL
-	NULL
ences	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
result	NULL
in	NULL
qualitatively	NULL
different	NULL
out-thermore	NULL
,	NULL
they	NULL
showed	NULL
that	NULL
this	NULL
phenotype	NULL
could	NULL
be	NULL
repro-	NULL
-	NULL
comes	NULL
(	NULL
``	NULL
all	NULL
or	NULL
none	NULL
response	NULL
``	NULL
)	NULL
(	NULL
54	NULL
)	NULL
.	NULL

However	NULL
,	NULL
these	NULL
biochemical	NULL
duced	NULL
either	NULL
by	NULL
treatment	NULL
with	NULL
the	NULL
PI3-K	NULL
inhibitor	NULL
wortman-	NULL
_	NULL
differences	NULL
do	NULL
not	NULL
exclude	NULL
other	NULL
operational	NULL
means	NULL
by	NULL
which	NULL
B7	NULL
nin	NULL
or	NULL
by	NULL
mutation	NULL
of	NULL
the	NULL
tyrosine	NULL
residues	NULL
in	NULL
the	NULL
PI3-K-	NULL
ligands	NULL
may	NULL
contribute	NULL
in	NULL
differing	NULL
outcomes	NULL
in	NULL
T	NULL
cell	NULL
rebinding	NULL
motif	NULL
of	NULL
CD19	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
-	NULL
sponses	NULL
and	NULL
differentiation	NULL
.	NULL

Clearly	NULL
,	NULL
if	NULL
CD80	NULL
and	NULL
CD86	NULL
are	NULL
correlation	NULL
between	NULL
PI3-K	NULL
recruitment	NULL
and	NULL
PLC-y1	NULL
activation	NULL
.	NULL

-	NULL
able	NULL
to	NULL
direct	NULL
T	NULL
cell	NULL
differentiation	NULL
and	NULL
functional	NULL
program	NULL
,	NULL
Whether	NULL
the	NULL
correlation	NULL
is	NULL
explained	NULL
by	NULL
the	NULL
recent	NULL
observation	NULL
-	NULL
differential	NULL
expression	NULL
of	NULL
B7	NULL
family	NULL
members	NULL
represent	NULL
an-that	NULL
binding	NULL
of	NULL
phosphatidylinositol	NULL
3,4,5-triphosphate	NULL
to	NULL
the	NULL
-	NULL
other	NULL
mechanism	NULL
by	NULL
which	NULL
CD28	NULL
and	NULL
CTLA-4-dependent	NULL
co-pleckstrin	NULL
homology	NULL
domain	NULL
of	NULL
PLC-y1	NULL
results	NULL
in	NULL
targeting	NULL
of	NULL
-	NULL
stimulatory	NULL
responses	NULL
are	NULL
regulated	NULL
.	NULL

The	NULL
affinities	NULL
of	NULL
both	NULL
PLC-y1	NULL
to	NULL
the	NULL
membrane	NULL
remains	NULL
to	NULL
be	NULL
shown	NULL
(	NULL
49	NULL
)	NULL
.	NULL

CD80	NULL
and	NULL
CD86	NULL
for	NULL
CD28	NULL
are	NULL
low	NULL
,	NULL
and	NULL
thus	NULL
the	NULL
outcome	NULL
of	NULL
an	NULL
We	NULL
and	NULL
others	NULL
(	NULL
19-22	NULL
)	NULL
also	NULL
found	NULL
several	NULL
shared	NULL
biochemical	NULL
_	NULL
in	NULL
vivo	NULL
immune	NULL
response	NULL
will	NULL
depend	NULL
upon	NULL
the	NULL
level	NULL
of	NULL
CD80	NULL
events	NULL
triggered	NULL
by	NULL
stimulation	NULL
with	NULL
either	NULL
CD80	NULL
or	NULL
CD86	NULL
.	NULL

-	NULL
and	NULL
CD86	NULL
expression	NULL
on	NULL
local	NULL
antigen-presenting	NULL
cells	NULL
.	NULL

Our	NULL
Both	NULL
ligands	NULL
were	NULL
capable	NULL
of	NULL
inducing	NULL
the	NULL
rapid	NULL
tyrosine	NULL
phos-	NULL
-	NULL
data	NULL
provide	NULL
further	NULL
evidence	NULL
that	NULL
even	NULL
in	NULL
relatively	NULL
similar	NULL
phorylation	NULL
of	NULL
signaling	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
earliest	NULL
stages	NULL
_	NULL
environments	NULL
,	NULL
wherein	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
both	NULL
ligands	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
including	NULL
VAV	NULL
and	NULL
CBL	NULL
.	NULL

VAV	NULL
has	NULL
been	NULL
_	NULL
is	NULL
equivalent	NULL
and	NULL
other	NULL
potentially	NULL
costimulatory	NULL
molecules	NULL
are	NULL
shown	NULL
to	NULL
bind	NULL
the	NULL
tyrosine	NULL
kinase	NULL
Zap-70	NULL
and	NULL
Slp-76	NULL
and	NULL
may	NULL
-	NULL
comparable	NULL
,	NULL
and	NULL
wherein	NULL
the	NULL
responding	NULL
T	NULL
cell	NULL
(	NULL
s	NULL
)	NULL
is/are	NULL
iden-bind	NULL
to	NULL
adapter	NULL
proteins	NULL
such	NULL
as	NULL
Grb2	NULL
and	NULL
She	NULL
as	NULL
well	NULL
as	NULL
the	NULL
_	NULL
tical	NULL
,	NULL
CD80	NULL
and	NULL
CD86	NULL
differ	NULL
in	NULL
their	NULL
capacity	NULL
to	NULL
stimulate	NULL
the	NULL
nuclear	NULL
proteins	NULL
Ku-70	NULL
and	NULL
human	NULL
ribonucleoprotein-K	NULL
(	NULL
re-	NULL
-	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
,	NULL
the	NULL
recruitment	NULL
of	NULL
PI3-K	NULL
to	NULL
viewed	NULL
in	NULL
Ref	NULL
.	NULL

50	NULL
)	NULL
.	NULL

More	NULL
recent	NULL
data	NULL
indicate	NULL
that	NULL
phosphoryl-	NULL
-	NULL
CD28	NULL
,	NULL
and	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLC-y1	NULL
.	NULL

These	NULL
dif-ated	NULL
VAV	NULL
is	NULL
an	NULL
exchange	NULL
factor	NULL
for	NULL
Rac-1	NULL
and	NULL
that	NULL
VAV-GEF	NULL
is	NULL
-	NULL
ferences	NULL
demonstrate	NULL
the	NULL
potential	NULL
for	NULL
ligand-specific	NULL
regula-enhanced	NULL
by	NULL
incubation	NULL
with	NULL
the	NULL
Sre	NULL
family	NULL
kinase	NULL
Lck	NULL
(	NULL
30	NULL
)	NULL
.	NULL

tion	NULL
of	NULL
CD28-dependent	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
.	NULL

Our	NULL
findings	NULL
confirmed	NULL
the	NULL
prior	NULL
demonstration	NULL
that	NULL
both	NULL
-	NULL
Taken	NULL
together	NULL
,	NULL
both	NULL
the	NULL
context	NULL
and	NULL
environment	NULL
of	NULL
T	NULL
cell	NULL
CD80	NULL
and	NULL
CD86	NULL
induce	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
VAV	NULL
_	NULL
stimulation	NULL
and	NULL
ligand-specific	NULL
signaling	NULL
cascades	NULL
are	NULL
able	NULL
to	NULL
(	NULL
19	NULL
)	NULL
.	NULL

We	NULL
have	NULL
also	NULL
demonstrated	NULL
that	NULL
both	NULL
CD80	NULL
and	NULL
CD86	NULL
are	NULL
-	NULL
contribute	NULL
to	NULL
regulation	NULL
of	NULL
T	NULL
cell	NULL
differentiation	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
3124	NULL
N	NULL
1	NULL
go	NULL
~	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

18	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22.	NULL
.	NULL

Gillis	NULL
,	NULL
S.	NULL
,	NULL
Ferm	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Ou	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

120	NULL
,	NULL
24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

REFERENCES	NULL
.	NULL

Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
71	NULL
,	NULL
1065-1068	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Vandenberghe	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Chem	NULL
.	NULL

Immunol	NULL
.	NULL

59	NULL
,	NULL
62-90	NULL
.	NULL

Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
1849-1356	NULL
.	NULL

Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Greene	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Brady	NULL
,	NULL
W.	NULL
,	NULL
Bajorath	NULL
,	NULL
J.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Peach	NULL
,	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Immunity	NULL
7983-801	NULL
.	NULL

Greene	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Leytze	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Emswiler	NULL
,	NULL
J.	NULL
,	NULL
Peach	NULL
,	NULL
R.	NULL
,	NULL
Bajorath	NULL
,	NULL
J.	NULL
,	NULL
Cosand	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
26762-26771	NULL
.	NULL

Truneh	NULL
,	NULL
A.	NULL
,	NULL
Reddy	NULL
,	NULL
M.	NULL
,	NULL
Ryan	NULL
,	NULL
P.	NULL
,	NULL
Lyn	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
Kichman	NULL
,	NULL
C.	NULL
,	NULL
Couez	NULL
,	NULL
D.	NULL
,	NULL
Hurle	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Sekaly	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Sweet	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Immunol	NULL
.	NULL

33	NULL
,	NULL
321-334	NULL
.	NULL

Kariv	NULL
,	NULL
L.	NULL
,	NULL
Truneh	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Sweet	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

157	NULL
,	NULL
29-38	NULL
.	NULL

Ellis	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Burden	NULL
,	NULL
M.	NULL
N.	NULL
,	NULL
Vinogradov	NULL
,	NULL
D.	NULL
V.	NULL
,	NULL
Linge	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Crowe	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
2700-2709	NULL
.	NULL

Peach	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Bajorath	NULL
,	NULL
J.	NULL
,	NULL
Naemura	NULL
,	NULL
J.	NULL
,	NULL
Leytze	NULL
,	NULL
G.	NULL
,	NULL
Greene	NULL
,	NULL
J.	NULL
,	NULL
Aruffo	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
21181-21187	NULL
Boussictis	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Gribben	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Daley	NULL
J.	NULL
,	NULL
Gray	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
11059-11063	NULL
Hathcock	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Laszlo	NULL
,	NULL
G.	NULL
,	NULL
Pucillo	NULL
,	NULL
C.	NULL
,	NULL
Linsley	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Hodes	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
631-641	NULL
Lenschow	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Ho	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Sattar	NULL
,	NULL
H.	NULL
,	NULL
Rhee	NULL
,	NULL
L.	NULL
,	NULL
Gray	NULL
,	NULL
G.	NULL
,	NULL
Nabavi	NULL
,	NULL
N.	NULL
,	NULL
Herold	NULL
,	NULL
K.	NULL
C.	NULL
,	NULL
and	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
1145-1155	NULL
Kuchroo	NULL
,	NULL
V.	NULL
K.	NULL
,	NULL
Das	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Brown	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Ranger	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Zamvil	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Sobel	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Weiner	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Nabavi	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
707-718	NULL
Matulonis	NULL
,	NULL
U.	NULL
,	NULL
Dosiou	NULL
,	NULL
C.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
,	NULL
Lamont	NULL
,	NULL
C.	NULL
,	NULL
Mauch	NULL
,	NULL
P.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
Griffin	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
1126-1131	NULL
Gajewski	NULL
,	NULL
T.	NULL
F.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
465-472	NULL
Racke	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
Scott	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Quigley	NULL
,	NULL
L.	NULL
,	NULL
Gray	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Abe	NULL
,	NULL
R.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
Perrin	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

96	NULL
,	NULL
2195-2203	NULL
Eick	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Chang	NULL
,	NULL
D.	NULL
,	NULL
Wells	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
and	NULL
Turka	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Transplantation	NULL
64	NULL
,	NULL
1497-1499	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Boussictis	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
Anumanthan	NULL
,	NULL
A.	NULL
,	NULL
Bernstein	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Ke	NULL
,	NULL
X.-Y	NULL
.	NULL

,	NULL
Rennert	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Gray	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Gribben	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
and	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Immunity	NULL
2	NULL
,	NULL
528-532	NULL
Nunes	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Truneh	NULL
,	NULL
A.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
1591-1598	NULL
Nunes	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Battifora	NULL
,	NULL
M.	NULL
,	NULL
Woodgett	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Trunch	NULL
,	NULL
A.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Immunol	NULL
.	NULL

83	NULL
,	NULL
68-70	NULL
Ueda	NULL
,	NULL
Y.	NULL
,	NULL
Levine	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
Huang	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
Ward	NULL
,	NULL
S.	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
957-966	NULL
Cefai	NULL
,	NULL
D.	NULL
,	NULL
Cai	NULL
,	NULL
Y.-C.	NULL
,	NULL
Hu	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Rudd	NULL
,	NULL
C.	NULL
(	NULL
1996	NULL
)	NULL
Int	NULL
.	NULL

Immunity	NULL
8	NULL
,	NULL
1609-1616	NULL
2027-2032	NULL
Weiss	NULL
,	NULL
M.	NULL
,	NULL
Yokoyama	NULL
,	NULL
C.	NULL
,	NULL
Shikama	NULL
,	NULL
Y.	NULL
,	NULL
Naugle	NULL
,	NULL
C.	NULL
,	NULL
Druker	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Sicff	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Blood	NULL
82	NULL
,	NULL
3298-3306	NULL
Rooney	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Sun	NULL
,	NULL
Y.	NULL
L.	NULL
,	NULL
Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
and	NULL
Hoey	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
6299-6310	NULL
Hutchcroft	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Tsai	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Bierer	NULL
,	NULL
B.	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
13362-13370	NULL
Ward	NULL
,	NULL
S.	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

818	NULL
,	NULL
861-877	NULL
28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50.	NULL
.	NULL

Panchamoorthy	NULL
,	NULL
G.	NULL
,	NULL
Fukazawa	NULL
,	NULL
T.	NULL
,	NULL
Miyake	NULL
,	NULL
S.	NULL
,	NULL
Soltoff	NULL
,	NULL
S.	NULL
,	NULL
Reedquist	NULL
,	NULL
K.	NULL
,	NULL
52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

Differential	NULL
Signaling	NULL
through	NULL
CD28	NULL
by	NULL
Ligands	NULL
CD80	NULL
and	NULL
CD86	NULL
Margolis	NULL
,	NULL
B.	NULL
,	NULL
Hu	NULL
,	NULL
P.	NULL
,	NULL
Katzav	NULL
,	NULL
S.	NULL
,	NULL
Li	NULL
,	NULL
W.	NULL
,	NULL
Oliver	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Ullrich	NULL
,	NULL
A.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Schlessinger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
856	NULL
,	NULL
71-74	NULL
Nunes	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Collette	NULL
,	NULL
Y.	NULL
,	NULL
Truneh	NULL
,	NULL
A.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
1067-1076	NULL
Crespo	NULL
,	NULL
P.	NULL
,	NULL
Schuebel	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Ostrom	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Gutkind	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Bustelo	NULL
,	NULL
X.	NULL
R.	NULL
(	NULL
1997	NULL
)	NULL
Nature	NULL
885	NULL
,	NULL
169-172	NULL
Donovan	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Wange	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Langdon	NULL
,	NULL
W.	NULL
Y.	NULL
,	NULL
and	NULL
Samuelson	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
22921-22924	NULL
Marcilla	NULL
,	NULL
A.	NULL
,	NULL
Rivero-Lezcano	NULL
,	NULL
O.	NULL
M.	NULL
,	NULL
Agarwal	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Robbins	NULL
,	NULL
K.	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
9115-9120	NULL
Miyake	NULL
,	NULL
S.	NULL
,	NULL
Lupher	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Andoniou	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Lill	NULL
,	NULL
N.	NULL
L.	NULL
,	NULL
Ota	NULL
,	NULL
S.	NULL
,	NULL
Douillard	NULL
,	NULL
P.	NULL
,	NULL
Rao	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Band	NULL
,	NULL
H.	NULL
(	NULL
1997	NULL
)	NULL
Crit	NULL
.	NULL

Rev	NULL
.	NULL

Oncog	NULL
.	NULL

8	NULL
,	NULL
189-218	NULL
Pages	NULL
,	NULL
F.	NULL
,	NULL
Ragueneau	NULL
,	NULL
M.	NULL
,	NULL
Rottapel	NULL
,	NULL
R.	NULL
,	NULL
Trunch	NULL
,	NULL
A.	NULL
,	NULL
Nunes	NULL
,	NULL
J.	NULL
,	NULL
Imbert	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
.	NULL

Olive	NULL
,	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
869	NULL
,	NULL
327-329	NULL
Prasad	NULL
,	NULL
K.	NULL
V.	NULL
S.	NULL
,	NULL
Cai	NULL
,	NULL
Y.-C.	NULL
,	NULL
Raab	NULL
,	NULL
M.	NULL
,	NULL
Duckworth	NULL
,	NULL
B.	NULL
,	NULL
Cantley	NULL
,	NULL
L.	NULL
,	NULL
Shoelson	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
and	NULL
Rudd	NULL
,	NULL
C.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

91	NULL
,	NULL
2834-2838	NULL
.	NULL

Stein	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
3892-3402	NULL
.	NULL

Truitt	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Hicks	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
and	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179	NULL
,	NULL
1071-1076	NULL
Ward	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Westwick	NULL
,	NULL
J.	NULL
,	NULL
Hall	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
and	NULL
Sansom	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28	NULL
,	NULL
2572-2577	NULL
Ghiotto-Ragueneau	NULL
,	NULL
M.	NULL
,	NULL
Battifora	NULL
,	NULL
M.	NULL
,	NULL
Trunch	NULL
,	NULL
A.	NULL
,	NULL
Waterfield	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
and	NULL
Olive	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

26	NULL
,	NULL
84-41	NULL
Franke	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
Yang	NULL
,	NULL
S.	NULL
I.	NULL
,	NULL
T.	NULL
O.	NULL
,	NULL
Chan	NULL
,	NULL
Datta	NULL
,	NULL
K.	NULL
,	NULL
Kazlauskas	NULL
,	NULL
A.	NULL
,	NULL
Morrison	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
Kaplan	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
and	NULL
Tsichlis	NULL
,	NULL
P.	NULL
N.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
81	NULL
,	NULL
727-736	NULL
Burgering	NULL
,	NULL
B.	NULL
M.	NULL
T.	NULL
,	NULL
and	NULL
Coffer	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Nature	NULL
876	NULL
,	NULL
599-602	NULL
Chung	NULL
,	NULL
J.	NULL
,	NULL
Grammer	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
Lemon	NULL
,	NULL
K.	NULL
P.	NULL
,	NULL
Kazlauskas	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Blenis	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Nature	NULL
870	NULL
,	NULL
71-75	NULL
Weng	NULL
,	NULL
Q.	NULL
P.	NULL
,	NULL
Andrabi	NULL
,	NULL
K.	NULL
,	NULL
Kippel	NULL
,	NULL
A.	NULL
,	NULL
Kozlowski	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Williams	NULL
,	NULL
L.	NULL
T.	NULL
,	NULL
and	NULL
Avruch	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

92	NULL
,	NULL
5744-5748	NULL
.	NULL

Boutin	NULL
,	NULL
Y.	NULL
,	NULL
Letienberg	NULL
,	NULL
D.	NULL
,	NULL
Tao	NULL
,	NULL
X.	NULL
,	NULL
and	NULL
Bottomly	NULL
,	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

159	NULL
,	NULL
5802-5809	NULL
Smith	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Tso	NULL
,	NULL
J.	NULL
Y.	NULL
,	NULL
Clark	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Cole	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185	NULL
,	NULL
14183-1422	NULL
Yang	NULL
,	NULL
N.	NULL
N.	NULL
,	NULL
Venugopalan	NULL
,	NULL
M.	NULL
,	NULL
Hardikar	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Glasebrook	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
1222-1225	NULL
Nunes	NULL
,	NULL
J.	NULL
,	NULL
Klasen	NULL
,	NULL
S.	NULL
,	NULL
Ragueneau	NULL
,	NULL
M.	NULL
,	NULL
Paron	NULL
,	NULL
C.	NULL
,	NULL
Covez	NULL
,	NULL
D.	NULL
,	NULL
Mawas	NULL
,	NULL
C.	NULL
,	NULL
Bagnasco	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Olive	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

5	NULL
,	NULL
811-315	NULL
Buh	NULL
]	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Pleiman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Rickert	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
and	NULL
Cambier	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186	NULL
,	NULL
1897-1910	NULL
Falasca	NULL
,	NULL
M.	NULL
,	NULL
Logan	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Lehto	NULL
,	NULL
V.	NULL
P.	NULL
,	NULL
Baccante	NULL
,	NULL
G.	NULL
,	NULL
Lemmon	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Schlessinger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

17	NULL
,	NULL
414-422	NULL
Collins	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Deckert	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Altman	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
18	NULL
,	NULL
221-225	NULL
Druker	NULL
,	NULL
B.	NULL
,	NULL
Shoelson	NULL
,	NULL
S.	NULL
,	NULL
Cantley	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Band	NULL
,	NULL
H.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
3187-3194	NULL
Fukuda	NULL
,	NULL
T.	NULL
,	NULL
Kitamura	NULL
,	NULL
D.	NULL
,	NULL
Taniuchi	NULL
,	NULL
I.	NULL
,	NULL
Mackawa	NULL
,	NULL
Y.	NULL
,	NULL
Benhamou	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Sarthou	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Watanabe	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

92	NULL
,	NULL
7302-7306	NULL
Fournel	NULL
,	NULL
M.	NULL
,	NULL
Davidson	NULL
,	NULL
D.	NULL
,	NULL
Weil	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Veilette	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183	NULL
,	NULL
301-306	NULL
Ferrel	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
and	NULL
Machleder	NULL
,	NULL
E.	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
Science	NULL
280	NULL
,	NULL
895-898	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
CD80	NULL
and	NULL
CD86	NULL
Are	NULL
Not	NULL
Equivalent	NULL
in	NULL
Their	NULL
Ability	NULL
to	NULL
Induce	NULL
the	NULL
Tyrosine	NULL
Phosphorylation	NULL
of	NULL
CD28	NULL
Jacqueline	NULL
M.	NULL
Slavik	NULL
,	NULL
Jill	NULL
E.	NULL
Hutchcroft	NULL
and	NULL
Barbara	NULL
E.	NULL
Bierer	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1999	NULL
,	NULL
274:3116-3124.	NULL
doi	NULL
:	NULL
10.1074/jb0.274.5.3116	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/274/5/3116	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
53	NULL
references	NULL
,	NULL
32	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
16	NULL
full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

